


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:05Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407640" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407640</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>mabs</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">MAbs</journal-id><journal-id journal-id-type="iso-abbrev">MAbs</journal-id><journal-id journal-id-type="pmc-domain-id">934</journal-id><journal-id journal-id-type="pmc-domain">mabs</journal-id><journal-title-group><journal-title>mAbs</journal-title></journal-title-group><issn pub-type="ppub">1942-0862</issn><issn pub-type="epub">1942-0870</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407640</article-id><article-id pub-id-type="pmcid-ver">PMC12407640.1</article-id><article-id pub-id-type="pmcaid">12407640</article-id><article-id pub-id-type="pmcaiid">12407640</article-id><article-id pub-id-type="pmid">40888155</article-id><article-id pub-id-type="doi">10.1080/19420862.2025.2553622</article-id><article-id pub-id-type="publisher-id">2553622</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Report</subject></subj-group></article-categories><title-group><article-title>Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case study</article-title><alt-title alt-title-type="left-running-head">V. SIEGMUND ET AL.</alt-title><alt-title alt-title-type="right-running-head">MABS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Siegmund</surname><given-names initials="V">Vanessa</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0002" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Klewinghaus</surname><given-names initials="D">Daniel</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teroerde</surname><given-names initials="J">Jonas</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9259-0965</contrib-id><name name-style="western"><surname>Pekar</surname><given-names initials="L">Lukas</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-9977-9299</contrib-id><name name-style="western"><surname>Harwardt</surname><given-names initials="J">Julia</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4649-2843</contrib-id><name name-style="western"><surname>Zielonka</surname><given-names initials="S">Stefan</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Militano</surname><given-names initials="F">Francesca</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8490-7536</contrib-id><name name-style="western"><surname>Licari</surname><given-names initials="G">Giuseppe</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref><xref rid="an0003" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4643-1941</contrib-id><name name-style="western"><surname>Evers</surname><given-names initials="A">Andreas</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>a</label>Early Protein Supply &amp; Characterization, <institution-wrap><institution>Merck Healthcare KGaA</institution></institution-wrap>, <city>Darmstadt</city>, <country>Germany</country></aff><aff id="aff0002"><label>b</label>Antibody Discovery &amp; Protein Engineering, <institution-wrap><institution>Merck Healthcare KGaA</institution></institution-wrap>, <city>Darmstadt</city>, <country>Germany</country></aff><aff id="aff0003"><label>c</label>Institute for Organic Chemistry and Biochemistry, <institution-wrap><institution>Technical University of Darmstadt</institution></institution-wrap>, <city>Darmstadt</city>, <country>Germany</country></aff><aff id="aff0004"><label>d</label><institution-wrap><institution>Global Drug Product Development, Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany)</institution></institution-wrap>, <city>Fenil-sur-Corsier</city>, <country>Switzerland</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Andreas Evers <email xlink:href="mailto:Andreas.evers@merckgroup.com">Andreas.evers@merckgroup.com</email> Antibody Discovery &amp; Protein Engineering, Merck Healthcare KGaA, <addr-line>Frankfurter Stra&#223;e 250, D50-905</addr-line>, <city>Darmstadt</city><postal-code>64293</postal-code>, <country>Germany</country></corresp><corresp id="an0002">Vanessa Siegmund <email xlink:href="mailto:Vanessa.Siegmund@merckgroup.com">Vanessa.Siegmund@merckgroup.com</email> Early Protein Supply &amp; Characterization, Merck Healthcare KGaA, Frankfurter Stra&#223;e 250, D-64293 Darmstadt, Germany</corresp><corresp id="an0003">Giuseppe Licari <email xlink:href="mailto:Giuseppe.Licari@merckgroup.com">Giuseppe.Licari@merckgroup.com</email> Biotech Development Center, Merck Serono SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>1</day><month>9</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>17</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">477326</issue-id><elocation-id seq="83">2553622</elocation-id><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 16:25:19.050"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>01</day><month>9</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>01</day><month>9</month><year>2025</year></date></event><event event-type="received"><date><day>25</day><month>6</month><year>2025</year></date></event><event event-type="revised"><date><day>21</day><month>8</month><year>2025</year></date></event><event event-type="accepted"><date><day>22</day><month>8</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="KMAB_17_2553622.pdf"/><self-uri content-type="pdf" xlink:href="KMAB_17_2553622.pdf"/><abstract><title>ABSTRACT</title><p>The discovery and development of multispecific antibodies present unique challenges in optimizing their physicochemical properties to enhance developability and manufacturability. Common developability challenges include increased risk of aggregation, high viscosity, poor solubility, low expression yields, complex purification requirements, greater propensity for fragmentation, immunogenicity, or pharmacokinetics. In this study, we systematically investigate the solution behavior of engineered bispecific IgG1-VHH constructs derived from a parental NKp30 &#215;EGFR natural killer cell engager (NKCE) molecule, focusing on colloidal stability, hydrophobicity, thermal stability, pH sensitivity, and viscosity. By combining <italic toggle="yes">in silico</italic> predictions and experimental evaluations, we engineered variants with altered isoelectric points (pIs) of the Fab and VHH domains and characterized them across a broad, formulation-relevant pH range (pH 4.5&#8211;8.0). Our findings indicate that aligning slightly basic pI profiles (approximately 7.5&#8211;9.0) across variable domains within bispecific antibodies can effectively mitigate charge asymmetries in standard acidic formulations that may lead to unfavorable solution behavior. Importantly, rational design and early-stage experimental validation yielded optimized variants exhibiting significantly improved colloidal stability and viscosity compared to the starting molecule. This systematic study, the first of its kind for bispecific antibodies, highlights the value of integrating domain-level <italic toggle="yes">in silico</italic> assessments early in antibody design, facilitating efficient optimization toward improved solution behavior of multispecific biotherapeutics.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Antibody engineering</kwd><kwd>colloidal stability</kwd><kwd>formulations</kwd><kwd><italic toggle="yes">in silico</italic> developability</kwd><kwd>isoelectric point</kwd><kwd>multispecific antibodies</kwd><kwd>viscosity</kwd></kwd-group><support-group><funding-group><funding-statement>The author(s) reported there is no funding associated with the work featured in this article.</funding-statement></funding-group></support-group><counts><fig-count count="7"/><table-count count="4"/><ref-count count="85"/><page-count count="22"/><word-count count="9698"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><p>Multispecific antibodies represent a rapidly expanding class of biotherapeutics with the potential to address complex diseases by engaging multiple targets or pathways within a single molecule.<sup><xref rid="cit0001" ref-type="bibr">1&#8211;5</xref></sup> This molecular versatility enables novel mechanisms of action, such as dual antigen targeting for enhanced efficacy, immune cell redirection, or overcoming resistance mechanisms in oncology and beyond. Modular domains such as VHHs are particularly valuable building blocks for generating bi- and multispecific antibodies with tailored functional properties.<sup><xref rid="cit0006" ref-type="bibr">6&#8211;12</xref></sup> For example, an NKp30 &#215;EGFR natural killer cell engager (NKCE) is a bispecific construct designed to simultaneously bind the activating receptor NKp30 on NK cells and the epidermal growth factor receptor (EGFR) on tumor cells, thereby promoting targeted immune cell-mediated cytotoxicity for the treatment of solid tumors.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup></p><p>However, the structural complexity and modularity of multispecific formats introduce unique challenges for analytical characterization and pharmaceutical development.<sup><xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0015" ref-type="bibr">15</xref></sup> Common developability challenges include increased risk of aggregation, high viscosity, poor solubility, low expression yields, complex purification requirements, greater propensity for fragmentation, immunogenicity, or pharmacokinetics. These issues are often more pronounced in engineered constructs, as they lack the evolutionary &#8220;pre-selection&#8221; for stability found in canonical IgG antibodies. Conventional monoclonal antibodies (mAbs) tend to exhibit fewer developability risks because their architecture is based on naturally occurring IgG molecules, which have evolved for optimal stability, solubility, and function in the physiological environment. Furthermore, established antibody discovery pipelines, such as hybridoma technology and phage display, often incorporate selection pressures that favor well-expressed and stable candidates, further enriching for developable molecules.<sup><xref rid="cit0016" ref-type="bibr">16&#8211;20</xref></sup></p><p>Early prediction and optimization of physicochemical properties are critical to reduce attrition rates and accelerate development timelines of antibodies.<sup><xref rid="cit0021" ref-type="bibr">21&#8211;32</xref></sup> Physical stability, solubility, and aggregation propensity in solution present substantial barriers to successful progression from discovery to clinical application and commercialization. To address these risks, a variety of analytical techniques have been established to assess these attributes at early stages of drug discovery.<sup><xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0033" ref-type="bibr">33&#8211;36</xref></sup> including size-exclusion chromatography (SEC), differential scanning calorimetry (DSC), differential scanning fluorimetry (DSF), dynamic light scattering (DLS), analytical centrifugation with sedimentation interaction detection (AC-SINS), critical solution temperature with sedimentation interaction detection (CS-SINS), and polyethylene glycol (PEG) solubility assays. These assays provide valuable insights into antibody physicochemical profiles, enabling early identification of potential solubility issues and informed candidate prioritization or optimization.</p><p>Colloidal stability, reflecting the balance of attractive and repulsive forces between protein molecules, can be assessed by the diffusion interaction parameter (kD) measured by DLS, which correlates with the second virial coefficient B22.<sup><xref rid="cit0037" ref-type="bibr">37</xref></sup> High kD values indicate net-repulsive interactions, whereas low kD values indicate attractive forces, potentially leading to aggregation. Colloidal stability is a key predictor of solution attributes such as viscosity, opalescence, and aggregation tendency.<sup><xref rid="cit0028" ref-type="bibr">28</xref>,<xref rid="cit0038" ref-type="bibr">38</xref></sup> Stable colloidal formulations minimize aggregation and precipitation risks, ensuring consistent dosing and performance, particularly important for liquid formulations, which are increasingly preferred due to ease of administration and improved patient compliance.<sup><xref rid="cit0039" ref-type="bibr">39</xref></sup> Low colloidal stability complicates formulation and delivery of therapeutic antibodies, especially in subcutaneous applications, where increased viscosity and injection force required may exceed patient comfort limits. Favorable solution behavior over a broad pH range is also essential during manufacturing steps, such as viral inactivation, as stable solutions are less prone to aggregation. Thus, understanding the factors influencing colloidal stability is critical for successful antibody development.</p><p>Numerous studies have demonstrated that poor solution behavior of classical monospecific IgG1 antibody arises predominantly from attractive Fab &#8211; Fab and/or Fab &#8211; Fc interactions,<sup><xref rid="cit0040" ref-type="bibr">40&#8211;45</xref></sup> driven by electrostatic and hydrophobic properties such as overall charge, charge asymmetries, dipole moments, isoelectric points (pIs), and hydrophobic surface patches.<sup><xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0046" ref-type="bibr">46&#8211;49</xref></sup></p><p>Various <italic toggle="yes">in silico</italic> and machine learning (ML) methods have been developed to predict antibody solution behavior.<sup><xref rid="cit0027" ref-type="bibr">27</xref>,<xref rid="cit0050" ref-type="bibr">50&#8211;52</xref></sup> These approaches enable rapid <italic toggle="yes">in silico</italic> screening of large antibody datasets, providing predictive insights to identify or design improved therapeutic candidates prior to experimental testing. However, existing <italic toggle="yes">in silico</italic> methods primarily predict properties related to the variable domains of classical antibodies only. While this approach is effective for classical antibodies with identical constant regions, it becomes problematic for variants with different variable domain architectures (e.g., VHHs), constant region modifications,<sup><xref rid="cit0053" ref-type="bibr">53</xref>,<xref rid="cit0054" ref-type="bibr">54</xref></sup> or multispecific formats,<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup> where different domains are combined in various configurations. The integration of diverse binding entities within a single molecule introduces solubility risks, as additional domains can induce new dipole moments, charge asymmetries, and self-association via electrostatic or hydrophobic interactions. Generation and validation of predictive <italic toggle="yes">in silico</italic> and ML models for multispecific antibody properties, however, are limited by the scarcity of suitable training datasets adequately representing the diversity of multispecific antibody formats.<sup><xref rid="cit0055" ref-type="bibr">55</xref></sup> Moreover, many existing <italic toggle="yes">in silico</italic> models do not explicitly account for extrinsic factors that significantly influence antibody solution behavior. Variations in buffer composition, including differences in pH and ionic strength, strongly influence apparent antibody charges, self-interaction strength, and physical stability.<sup><xref rid="cit0056" ref-type="bibr">56&#8211;58</xref></sup> Consequently, combining datasets from different studies or publications to create comprehensive models is challenging, as these extrinsic factors can lead to inconsistent predictions and limit the applicability of ML models.</p><p>Notably, among various structure- and sequence-based <italic toggle="yes">in silico</italic> descriptors, pI has emerged as a particularly simple and powerful predictor of monospecific antibody solution behavior. For example, in a comprehensive analysis of 83 monospecific IgG1 antibodies, Mock et al.<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup> demonstrated that sequence-based pI showed the strongest correlation with colloidal stability (kD), outperforming all computed structure-based descriptors (Spearman <italic toggle="yes">r</italic>&#8201;=&#8201;0.85). Similarly, Makowski et al.<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup> reported that an Fv pI cutoff of&#8201;&gt;&#8201;6.3 provided strong discrimination between low- and high-viscosity monospecific antibodies (AUC&#8201;=&#8201;0.87). These studies underscore that, despite the complexity of protein solution behavior, pI effectively captures key electrostatic properties, making it an attractive simple parameter for early-stage <italic toggle="yes">in silico</italic> assessment and optimization of variable domains.</p><p>Here, we systematically investigate and optimize the solution behavior of bispecific IgG1-VHH constructs using physics-based <italic toggle="yes">in silico</italic> predictors combined with comprehensive experimental validation. This represents the first systematic study specifically addressing solution behavior of bispecific antibodies. We started from a previously characterized bispecific NKp30 &#215;EGFR NKCE, where NKp30-targeting VHH paratopes were fused via a (G4S)3 linker to the C-terminus of a classical IgG1 antibody, directed against EGFR.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> Initial <italic toggle="yes">in silico</italic> sequence assessments revealed charge asymmetries between Fab and VHH domains, potentially leading to unfavorable solution behavior through electrostatic-driven self-association. We hypothesized that engineering variants with similar, slightly basic pI profiles across these domains could mitigate the charge asymmetries, thereby improving colloidal stability, viscosity, and overall developability. To test this hypothesis, we experimentally evaluated a set of engineered variants across relevant formulation buffers (pH 4.5, 5.5, 6.5, 8.0) using multiple analytical methods (SEC, nanoDSF, DLS, HIC, imaged capillary isoelectric focusing (icIEF)). Additionally, we correlated experimentally observed solution behaviors with <italic toggle="yes">in silico</italic> descriptors computed from structural models at corresponding buffer pH and ionic strength values. Ultimately, optimized variants demonstrated improved colloidal stability and viscosity compared to the starting molecule. Our findings support the pragmatic use of similar, slightly basic variable domain pI values as an additional design criterion during early-stage optimization of multispecific antibodies.</p></sec><sec disp-level="1" id="s0002"><title>Results</title><sec disp-level="2" id="s0002-s2001"><title>Design of Fab and VHH variants and in silico assessments of domains and full constructs</title><p>An initial <italic toggle="yes">in silico</italic> assessment of the bispecific NKp30 &#215;EGFR NKCE starting molecule, termed Fab<sub>M</sub>-Fc-VHH<sub>L</sub> (<xref rid="f0001" ref-type="fig">Figure 1a,b</xref>), revealed a computed pI of 8.4 for the Fab domain (Fab<sub>M</sub> in <xref rid="t0001" ref-type="table">Table 1</xref>.) and a pI of 4.5 for the VHH (VHH<sub>L</sub> in <xref rid="t0001" ref-type="table">Table 1</xref>). This resulted in opposite charges of these domains across the pH range of 5.5 to 8.0 (<xref rid="t0001" ref-type="table">Table 1</xref>), creating charge asymmetries that could trigger electrostatic-induced self-interactions and potentially lead to aggregation and poor solution behavior.
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Bispecific NKCEs and the design of pI variants. (a) Schematic depiction of the starting molecule and the design of pI variants for the Fab and VHH domains, using color and shape coding to indicate high (blue), medium (gray), and low (red) pI for Fab (four-block) and VHH (single-block) domains. (b) Schematic representation of all engineered pI variant constructs, including control molecules. (c) Overview of analytical methods and molecule characteristics investigated in this study, used to correlate experimental data with <italic toggle="yes">in silico</italic> property calculations. The figure was generated with biorender (<ext-link xlink:href="https://www.biorender.com" ext-link-type="uri">https://www.biorender.com</ext-link>).</p></caption><alt-text>Schematic illustration of bispecific NKCE constructs and the design of pI variants. (a) Starting molecule with color-coded domains: high pI (blue), medium pI (gray), and low pI (red) for Fab (four-block) and VHH (single-block) domains. (b) Representation of engineered pI variant constructs, including control molecules. (c) Overview of experimental methods and molecule properties analyzed, highlighting correlations between experimental data and in silico calculations.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0001_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0001_PB.jpg"/></alternatives></fig><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Computed pI values and charges at four different pH values for the VHH, Fab and Fc domains of all molecules considered in this study.</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><tbody><tr><td align="left" colspan="1" rowspan="1"><inline-graphic id="ilg0001" xlink:href="KMAB_A_2553622_ILG0001.jpg"/></td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p>Subscript letters H, M, and L correspond to high, intermediate, and low pI variants, respectively. The charge values are color-coded, with positive charges indicated in blue and negative charges in red, facilitating visual interpretation of the electrostatic characteristics of the constructs at different pH values.</p></fn></table-wrap-foot></table-wrap></p><p>To systematically investigate the impact of these electrostatic features and validate our hypothesis that maintaining balanced and slightly basic pI values across domains improves solution behavior, we intentionally engineered variants covering a broad range of pI and charge profiles. Specific mutations were introduced into the VHH and Fab regions to generate variants with low, intermediate, and high pI values (termed VHH<sub>L</sub>, Fab<sub>L</sub>, VHH<sub>M</sub>, Fab<sub>M</sub>, VHH<sub>H</sub> and Fab<sub>H</sub>; <xref rid="f0001" ref-type="fig">Figure 1b,c</xref> and <xref rid="t0001" ref-type="table">Table 1</xref>). The rationale for selecting mutation positions and structure-activity relationship (SAR) analysis of binding affinities are provided in the Supplemental Materials (&#8220;Design of variable region pI variants, binding affinities and SAR analysis&#8221; and Figures S1, S2). Including the parental sequence, we generated three Fab variants and three VHH variants (Figure S1), which were combined into nine multispecific IgG-VHH constructs and six control molecules (three IgGs and three Fc-VHH constructs) for production and experimental profiling.</p><p>In our engineering strategy, we focused on varying the pI values of the variable domains (Fab and VHH), while the Fc domain was maintained as a clinically validated wild-type IgG1 sequence (pI&#8201;~&#8201;7.2) across all constructs for regulatory and manufacturability reasons. Although the Fc domain was not modified, it can also contribute to charge asymmetries depending on the formulation pH and the pI values of the variable domains. Therefore, computed charges for the Fc domain at pH 4.5&#8211;8.0 are provided in <xref rid="t0001" ref-type="table">Table 1</xref>. to enable comprehensive assessment of domain-level charge distributions.</p><p>For all 15 constructs, we computed pI values and charges at formulation-relevant pH values (4.5, 5.5, 6.5, and 8.0), selected to reflect the typical range used in commercial antibody formulations and to systematically cover conditions inducing different domain charges, depending on their pI values. Experimental pI measurements (<xref rid="t0002" ref-type="table">Table 2</xref>) were performed to validate these computational predictions, indicating good correlation between predicted and experimental values, with some variability only in the absolute values (Supplemental Material, &#8220;Isoelectric point determination&#8221; and Figures S3, S4).<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Experimentally determined pI values and the range of additional potential main species peaks (&#177;) and computed pI values and charges at different pH values for all engineered constructs. Experimental uncertainties may arise from variations in experimental conditions or inherent protein heterogeneity.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="&#xB1;" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Name</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">Experimental pI (&#177;)</th><th align="center" char="." colspan="1" rowspan="1">pI computed</th><th align="center" char="." colspan="1" rowspan="1">Charge (pH4.5)</th><th align="center" char="." colspan="1" rowspan="1">Charge (pH5.5)</th><th align="center" char="." colspan="1" rowspan="1">Charge (pH6.5)</th><th align="center" char="." colspan="1" rowspan="1">Charge (pH8.0)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Fc-VHH<sub>H</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">8.6 &#177; 0.4</td><td align="char" char="." colspan="1" rowspan="1">8.0</td><td align="char" char="." colspan="1" rowspan="1">23.7</td><td align="char" char="." colspan="1" rowspan="1">10.2</td><td align="char" char="." colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Fc-VHH<sub>M</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7.7 &#177; 0.3</td><td align="char" char="." colspan="1" rowspan="1">7.2</td><td align="char" char="." colspan="1" rowspan="1">21.7</td><td align="char" char="." colspan="1" rowspan="1">8.2</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="char" char="." colspan="1" rowspan="1">&#8722;1.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Fc-VHH<sub>L</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">6.1 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">5.9</td><td align="char" char="." colspan="1" rowspan="1">17.7</td><td align="char" char="." colspan="1" rowspan="1">3.4</td><td align="char" char="." colspan="1" rowspan="1">&#8722;3</td><td align="char" char="." colspan="1" rowspan="1">&#8722;6.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc-VHH<sub>H</sub><sup>a)</sup></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9.5 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">8.7</td><td align="char" char="." colspan="1" rowspan="1">50.7</td><td align="char" char="." colspan="1" rowspan="1">26.5</td><td align="char" char="." colspan="1" rowspan="1">15.5</td><td align="char" char="." colspan="1" rowspan="1">8.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc-VHH<sub>M</sub><sup>a)</sup></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9.4 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">8.6</td><td align="char" char="." colspan="1" rowspan="1">48.7</td><td align="char" char="." colspan="1" rowspan="1">24.5</td><td align="char" char="." colspan="1" rowspan="1">13.5</td><td align="char" char="." colspan="1" rowspan="1">6.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc-VHH<sub>L</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9.0 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">8.2</td><td align="char" char="." colspan="1" rowspan="1">44.7</td><td align="char" char="." colspan="1" rowspan="1">19.7</td><td align="char" char="." colspan="1" rowspan="1">8.5</td><td align="char" char="." colspan="1" rowspan="1">1.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc-VHH<sub>H</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9.0 &#177; 0.1</td><td align="char" char="." colspan="1" rowspan="1">8.3</td><td align="char" char="." colspan="1" rowspan="1">45.4</td><td align="char" char="." colspan="1" rowspan="1">20.6</td><td align="char" char="." colspan="1" rowspan="1">9.5</td><td align="char" char="." colspan="1" rowspan="1">2.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc-VHH<sub>M</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">8.8 &#177; 0.1</td><td align="char" char="." colspan="1" rowspan="1">8.1</td><td align="char" char="." colspan="1" rowspan="1">43.4</td><td align="char" char="." colspan="1" rowspan="1">18.6</td><td align="char" char="." colspan="1" rowspan="1">7.5</td><td align="char" char="." colspan="1" rowspan="1">0.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc-VHH<sub>L</sub><sup>b)</sup></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7.4 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">7.0</td><td align="char" char="." colspan="1" rowspan="1">39.5</td><td align="char" char="." colspan="1" rowspan="1">13.8</td><td align="char" char="." colspan="1" rowspan="1">2.5</td><td align="char" char="." colspan="1" rowspan="1">&#8722;4.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>L</sub>-Fc-VHH<sub>H</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7.5 &#177; 0.3</td><td align="char" char="." colspan="1" rowspan="1">7.2</td><td align="char" char="." colspan="1" rowspan="1">41.6</td><td align="char" char="." colspan="1" rowspan="1">15</td><td align="char" char="." colspan="1" rowspan="1">3.5</td><td align="char" char="." colspan="1" rowspan="1">&#8722;3.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>L</sub>-Fc-VHH<sub>M</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7.1 &#177; 0.2</td><td align="char" char="." colspan="1" rowspan="1">6.7</td><td align="char" char="." colspan="1" rowspan="1">39.6</td><td align="char" char="." colspan="1" rowspan="1">13</td><td align="char" char="." colspan="1" rowspan="1">1.5</td><td align="char" char="." colspan="1" rowspan="1">&#8722;5.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>L</sub>-Fc-VHH<sub>L</sub></td><td align="char" char="&#xB1;" colspan="1" rowspan="1">6.1 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">6.1</td><td align="char" char="." colspan="1" rowspan="1">35.6</td><td align="char" char="." colspan="1" rowspan="1">8.1</td><td align="char" char="." colspan="1" rowspan="1">&#8722;3.4</td><td align="char" char="." colspan="1" rowspan="1">&#8722;10.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">9.5 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">8.7</td><td align="char" char="." colspan="1" rowspan="1">44.5</td><td align="char" char="." colspan="1" rowspan="1">23.3</td><td align="char" char="." colspan="1" rowspan="1">13.2</td><td align="char" char="." colspan="1" rowspan="1">7.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">8.7 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">8.2</td><td align="char" char="." colspan="1" rowspan="1">39.3</td><td align="char" char="." colspan="1" rowspan="1">17.4</td><td align="char" char="." colspan="1" rowspan="1">7.2</td><td align="char" char="." colspan="1" rowspan="1">1.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>L</sub>-Fc</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">6.9 &#177; 0.0</td><td align="char" char="." colspan="1" rowspan="1">6.7</td><td align="char" char="." colspan="1" rowspan="1">35.4</td><td align="char" char="." colspan="1" rowspan="1">11.8</td><td align="char" char="." colspan="1" rowspan="1">1.3</td><td align="char" char="." colspan="1" rowspan="1">&#8722;4.8</td></tr></tbody></table><table-wrap-foot><fn id="tfn0002"><p>a) optimized molecule(s)</p></fn><fn id="tfn0003"><p>b) starting molecule</p></fn></table-wrap-foot></table-wrap></p></sec><sec disp-level="2" id="s0002-s2002"><title>Production of constructs and experimental profiling</title><p>Transient transfection of ExpiCHO cells followed by protein A purification resulted in high purity (&#8201;&gt;&#8201;96%) for all engineered constructs, as confirmed by analytical SEC (see Table S1 for analytical data). Expression yields for the multispecific constructs varied considerably, with titers ranging from 34.5 to 142.6&#8201;mg/L, and notably, the Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>M</sub>-Fc-VHH<sub>H</sub> constructs exhibited the lowest titers (36.9 and 34.5&#8201;mg/L, respectively). To comprehensively assess their solution behavior and validate our computational predictions, we experimentally profiled all constructs using a set of predictive analytical methods including nanoDSF, hydrophobic interaction chromatography (HIC), colloidal stability measurements via DLS, and pH sensitivity experiments (<xref rid="f0001" ref-type="fig">Figure 1c</xref>). Unless otherwise noted, these experiments were conducted across four formulation buffers spanning a pH range typically used in commercial antibody formulations: 20&#8201;mM acetate (pH 4.5), 20&#8201;mM histidine (pH 5.5), 20&#8201;mM histidine (pH 6.5), and 20&#8201;mM TRIS (pH 8.0).</p><p>Notably, the Fc-VHH<sub>M</sub> construct could not be detected in histidine buffer at pH 6.5, and the Fab<sub>L</sub>-Fc-VHH<sub>L</sub> construct was undetectable in histidine buffers at both pH 5.5 and pH 6.5, likely due to aggregation under these conditions. Finally, viscosity measurements were conducted in two relevant formulation buffers (histidine at pH 5.5 and 6.5) for two constructs exhibiting the best overall developability profiles, as well as for the starting molecule, to experimentally confirm improvements in viscosity and overall solution behavior at high concentrations.</p></sec><sec disp-level="2" id="s0002-s2003"><title>Protein engineering significantly improves colloidal stability in relevant formulation buffers</title><p>Colloidal stability data for all bispecific and control constructs across four formulation buffers are provided in Table S2 and graphically displayed in <xref rid="f0002" ref-type="fig">Figure 2</xref> Colloidal stability was assessed using the diffusion interaction parameter (kD) as a surrogate measure. The starting molecule Fab<sub>M</sub>-Fc-VHH<sub>L</sub> from our previous study<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> exhibited unfavorable colloidal stability (kD&#8201;&lt;&#8201;&#8722;15&#8201;mL/g)<sup>18</sup> across all four formulation buffers, likely due to charge asymmetries in the domains at pH&#8201;&gt;&#8201;4.5 (see <xref rid="t0001" ref-type="table">Table 1</xref>. for computed charges), resulting in greater self-association than repulsion.
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>Colloidal stability data for all 15 variants in four different formulation buffers. A kD value of &#8722;15 ml/g, shown as red dotted line, or higher is typically preferred.<sup><xref rid="cit0018" ref-type="bibr">18</xref></sup></p></caption><alt-text>Bar chart presenting colloidal stability (kD values) for 15 bispecific and control antibody constructs across four formulation buffers: acetate pH 4.5, histidine pH 5.5, histidine pH 6.5, and TRIS pH 8.0. The red dotted line indicates the preferred kD threshold of &#8722;15 mL/g for developability. Constructs include optimized molecules (green), starting molecules (red), and controls.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0002_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0002_PB.jpg"/></alternatives></fig></p><p>Encouragingly, the bispecific constructs Fab<sub>H</sub>-Fc-VHH<sub>M</sub> and Fab<sub>H</sub>-Fc-VHH<sub>H</sub> (termed <italic toggle="yes">optimized molecules</italic> in <xref rid="f0002" ref-type="fig">Figure 2</xref> hereafter), which incorporate Fab and VHH variants designed for higher pIs, demonstrate favorable colloidal stability in formulation buffers at pH 4.5, 5.5, and 6.5, while exhibiting unfavorable stability only at pH 8.0. These findings align well with the computed charge profiles of the Fab<sub>H</sub>, VHH<sub>H</sub>, VHH<sub>M</sub> and Fc domains at these pH values (<xref rid="t0001" ref-type="table">Table 1</xref>), where all domains show positive charges up to pH 6.5, with charge asymmetries emerging only at pH 8.0.</p><p>In addition to these promising results, several trends emerged from structure-property analysis:
<list list-type="order" id="list_0001"><list-item><p><bold>Fab-Fc Variants</bold>: Within the three Fab-Fc variants, colloidal stability generally improved with increasing Fab domain charge across all buffers. The low pI variant FabL-Fc consistently exhibited unfavorable stability (kD&#8201;&lt;&#8201;&#8722;15&#8201;mL/g), consistent with literature evidence that Fab/Fv regions with negative charges in classical monospecific antibodies tend to self-interact with the Fc regions, particularly at acidic pH, where positive patches on the Fc region are more pronounced.<sup><xref rid="cit0027" ref-type="bibr">27</xref>,<xref rid="cit0054" ref-type="bibr">54</xref></sup> In comparison, the Fab<sub>M</sub>-Fc variant, with an increased Fab domain pI (8.4), showed slightly improved colloidal stability at pH values 4.5 - 6.5, but not at pH 8.0. In contrast, and in agreement with the computed charges, the high pI variant Fab<sub>H</sub>-Fc displayed improved kD values across the entire pH range, including positive kD values at pH 4.5 and 6.5.</p></list-item><list-item><p><bold>Fc-VHH Variants</bold>: The three Fc-VHH molecules generally demonstrated favorable colloidal stability (kD&#8201;&#8805;&#8201;&#8722;15&#8201;mL/g) in most formulation buffers. Notably, the high pI variant Fc-VHH<sub>H</sub> showed pronounced positive colloidal stability at pH 4.5, consistent with its computed charge and pI values. Interestingly, Fc-VHH<sub>H</sub> showed a marked decrease in colloidal stability when moving from pH 4.5 (acetate buffer) to pH 5.5 (histidine), followed by a slight recovery at pH 6.5. Similarly, Fc-VHH<sub>M</sub> demonstrated slightly improved colloidal stability at pH 6.5 compared to pH 5.5, despite the VHH domain (pI 6.7) carrying only a marginal positive charge at pH 6.5. Fc-VHH<sub>L</sub> was the most pronounced outlier, exhibiting unexpectedly high colloidal stability at pH 5.5, even though pI and charge calculations suggest charge asymmetries between the VHH and Fc domain at this pH. In summary, most, but not all, trends in the colloidal stability data of Fc-VHH constructs can be rationalized with the charge/pI model, with Fc-VHH<sub>L</sub> at pH 5.5 being the most striking outlier. The underlying molecular basis for such exceptions remains unclear, as detailed data on Fc-VHH solution behavior, particularly regarding the influence of the free N-terminal hinge region, which may exhibit enhanced flexibility and impact self-interaction differently than in classical antibodies, is lacking in the literature.</p></list-item><list-item><p><bold>Bispecific Constructs</bold>: A key trend among the bispecific constructs was that combining favorable Fab and VHH domains generally resulted in favorable bispecific constructs, although this relationship was not strictly linear. Overall, in alignment with the simple charge model, colloidal stability improved when the charges of all individual domains were sufficiently high to optimize electrostatic repulsion.</p></list-item></list></p><p>Another notable observation is that all molecules exhibited negative colloidal stability at pH 8.0 (TRIS buffer), except for Fc-VHH<sub>L</sub>, which showed a slightly positive kD value (1.1&#8201;mL/g). At this pH, the Fc region (pI 7.2) carries a slightly negative charge and may therefore self-interact with Fab or VHH domains that display pronounced positive patches at pH 8.0. The decrease in colloidal stability was less pronounced for Fc-VHH constructs and even reversed for Fc-VHH<sub>L</sub>, supporting the hypothesis that electrostatic interactions are influenced by the negative overall charge of both the Fc and VHH<sub>L</sub> domains at this pH.</p><p>As outlined above, we observed considerable differences in colloidal stability in histidine buffer at pH 6.5 compared to pH 5.5, which could not be fully explained by the simple charge model. This discrepancy may be attributed to additional buffer-related factors, such as differences in ionic strength, specific buffer-antibody interactions, or other environmental conditions influencing protein behavior, highlighting the complexity beyond simplified charge-based predictions. These observations regarding buffer-specific differences in colloidal stability, particularly between histidine buffers at pH 5.5 and 6.5, are further discussed below.</p><p>A key outcome of this study was the successful optimization of the <italic toggle="yes">starting molecule</italic> Fab<sub>M</sub>-Fc-VHH<sub>L</sub> to yield two <italic toggle="yes">optimized constructs</italic> (Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>H</sub>-Fc-VHH<sub>M</sub>) with significantly improved colloidal stability, particularly in histidine buffers (pH 5.5 and 6.5; see <xref rid="f0002" ref-type="fig">Figure 2</xref>). These formulation buffers are highly relevant for commercial antibody formulations, as highlighted by Martin et al.<sup><xref rid="cit0017" ref-type="bibr">17</xref></sup> Interestingly, formulating at a pH approximately 1&#8211;2 units away from a biotherapeutic&#8217;s overall pI, which is a widely applied guideline, did not always guarantee favorable solution behavior within this dataset. Variants with high overall computed pI, values (&#8805;8.1), such as Fab<sub>H</sub>-Fc-VHH<sub>L</sub>, Fab<sub>M</sub>-Fc-VHH<sub>H</sub>, and Fab<sub>M</sub>-Fc-VHH<sub>M</sub> (computed pI values of 8.2, 8.3, and 8.1, respectively), still exhibited unfavorable colloidal stability (kD&#8201;&lt;&#8201;&#8722;15&#8201;ml/g) in histidine at pH 5.5, despite all domains having a positive net charge at this pH.</p><p>In summary, our results clearly demonstrate that colloidal stability could be significantly enhanced in bispecific antibodies through charge engineering, supporting the relevance of balanced and appropriately basic pI profiles across domains.</p></sec><sec disp-level="2" id="s0002-s2004"><title>Optimized molecules have lower hydrophobicities compared to the starting molecule</title><p>Higher hydrophobicity is generally unfavorable for developability, as proteins with increased hydrophobicity regions are more prone to self-association and aggregation, potentially compromising stability not only in formulation, but also in manufacturing. Comparison of HIC retention times for the three IgG controls (Fab<sub>H</sub>-Fc, Fab<sub>M</sub>-Fc, and Fab<sub>L</sub>-Fc; Table S1 and <xref rid="f0003" ref-type="fig">Figure 3</xref>) revealed similar hydrophobicities for the three Fab pI variants, with retention times of 6.8, 6.7, and 6.5&#8201;minutes, respectively. In contrast, the VHH<sub>L</sub> domain present in the starting molecule exhibited a significantly longer retention time (7.2&#8201;minutes for Fc-VHH<sub>L</sub>), compared to Fc-VHH<sub>M</sub> (4.8&#8201;minutes) and Fc-VHH<sub>H</sub> (4.4&#8201;minutes). This increased retention time translates into higher retention times for all bispecific variants containing the VHH<sub>L</sub> domain relative to those containing VHH<sub>H</sub> and VHH<sub>M</sub>. These observed HIC shifts are somewhat surprising, since the VHH variants were engineered by substituting only polar residues with other polar residues to modulate charge, not hydrophobicity (Figure S1). Thus, these differences in HIC retention time potentially reflect not only differences in hydrophobicity, but rather changes in charge distribution and reduced conformational stability of VHH<sub>L</sub>. This interpretation is supported by literature showing that, in addition to classical hydrophobicity, HIC retention can also be influenced by charge distribution, conformational stability, and properties of the experimental setup such as ionic strength and buffer conditions.<sup><xref rid="cit0059" ref-type="bibr">59</xref>,<xref rid="cit0060" ref-type="bibr">60</xref></sup>
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><p>Graphical visualization of HIC retention times for all 15 constructs. The red dotted line at a retention time (RT) of 7.2&#160;minutes represents the retention time of the marketed antibody avelumab (Bavencio&#174;) as an assay control.</p></caption><alt-text>Bar chart illustrating hydrophobic interaction chromatography (HIC) retention times for 15 antibody constructs. The red dotted line at 7.2&#160;minutes represents the retention time of the marketed antibody avelumab, used as an assay control. Constructs include optimized molecules (green), starting molecules (red), and controls, with retention times displayed in minutes.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0003_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0003_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="2" id="s0002-s2005"><title>Protein engineering improves thermal stability for optimized constructs in all formulation buffers</title><p>Higher thermal stability indicates that a protein can maintain its structural integrity at elevated temperatures, which is crucial for stability during manufacturing, storage, and administration. The unfolding transition midpoint (Tm), reflecting the protein&#8217;s structure stability under heat, and onset temperature (Tonset), which provides insights into initial unfolding, are complementary descriptors to colloidal stability. While colloidal stability assesses protein-protein interactions in solution, thermal stability evaluates structural resilience upon heating. Both properties are essential for antibody developability, but they provide distinct insights: a protein may exhibit high thermal stability yet poor colloidal stability, or vice versa.</p><p>Protein thermal stability often decreases at lower pH values, as increased protonation of amino acid side chains can disrupt ionic interactions and hydrogen bonds essential for maintaining tertiary and quaternary structures.<sup><xref rid="cit0061" ref-type="bibr">61</xref>,<xref rid="cit0062" ref-type="bibr">62</xref></sup> This general trend was also observed in the Tm and Tonset values across all constructs of this study (<xref rid="f0004" ref-type="fig">Figure 4</xref> and Tables S3, S4). While all constructs exhibit Tonset values above 50&#176;C and Tm1 values above 55&#176;C, which are thresholds generally considered favorable for developability,<sup><xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0020" ref-type="bibr">20</xref></sup> at pH 6.5 and 8.0 several constructs show Tonset values below 50&#176;C at pH 4.5 and 5.5.
<fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4.</label><caption><p>Experimental melting temperatures (Tm1 and Tonset) for all 15 variants evaluated in four different formulation buffers. Red dashed lines indicate commonly accepted thresholds for Tonset (50&#176;C) and Tm1 (55&#176;C) for developability.<sup><xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0020" ref-type="bibr">20</xref></sup></p></caption><alt-text>Dual bar chart showing experimental melting temperatures (Tm1 and Tonset) for 15 antibody constructs across four formulation buffers: acetate pH 4.5, histidine pH 5.5, histidine pH 6.5, and TRIS pH 8.0. Red dashed lines indicate thresholds for developability: 50&#176;C for Tonset and 55&#176;C for Tm1. Constructs include optimized molecules (green), starting molecules (red), and controls.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0004_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0004_PB.jpg"/></alternatives></fig></p><p>Notably, the optimized bispecific constructs, Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>H</sub>-Fc-VHH<sub>M</sub>, demonstrated improved thermal stability compared to the starting molecule Fab<sub>M</sub>-Fc-VHH<sub>L</sub> across the entire pH range, underscoring the effectiveness of our engineering strategy.</p><p>Detailed domain-level analysis (see Supplemental Material, &#8220;Detailed analysis of DSF curves&#8221;) revealed that the domain with the lowest intrinsic stability &#8211; either the Fc CH2 domain or an unstable VHH domain &#8211; sets the Tonset for each construct. In particular, constructs containing the low-pI VHH<sub>L</sub> domain exhibited the lowest Tonset and Tm1 in acidic buffers, indicating that VHH<sub>L</sub> was the first to unfold, regardless of the presence of Fab or Fc regions. In contrast, in constructs with more stable VHH domains or lacking VHH domains, the Fc domain seems the primary driver of the lowest Tonset, especially at acidic pH, consistent with previous findings on the low conformational stability of CH2 under such conditions.<sup><xref rid="cit0063" ref-type="bibr">63&#8211;65</xref></sup></p><sec disp-level="3" id="s0002-s2005-s3001"><title>Experimental colloidal stability data correlate with charge-based in silico properties</title><p>Our intentional strategy of designing variants with diverse pI and charge profiles, combined with comprehensive experimental characterization, provided a broad dataset well-suited for exploring correlations between experimental colloidal stability and computed <italic toggle="yes">in silico</italic> descriptors. Such diversity in the property space is valuable for identifying molecular properties that influence solution behavior, which can guide future optimization efforts of multispecific antibodies. Structural models for all constructs were generated, and protein properties were computed at pH values of 4.5, 5.5, 6.5, and 8.0 using Molecular Operating Environment<sup><xref rid="cit0066" ref-type="bibr">66</xref></sup> (MOE) software (see Methods for details). The Pearson and Spearman correlation coefficients were calculated to assess the relationships between all experimental data and the computed properties (Table S5).</p><p>Among the experimental readouts, we observed only a strong correlation between Tm and Tonset (Spearman <italic toggle="yes">r</italic>&#8201;=&#8201;0.66, Pearson <italic toggle="yes">r</italic>&#8201;=&#8201;0.72). This confirms that thermal stability provides complementary insights into developability distinct from hydrophobicity and colloidal stability.</p><p>Analysis of correlations between experimental colloidal stability (kD values) and <italic toggle="yes">in silico</italic> descriptors revealed relationships with several computed parameters related to surface charge and hydrophobicity. Through a data analysis (see Methods section), we identified correlations between kD and the percentage area of positively charged surface patches (Spearman <italic toggle="yes">r</italic>&#8201;=&#8201;0.57, Pearson <italic toggle="yes">r</italic>&#8201;=&#8201;0.58), the percentage area of negatively charged surface patches (Spearman <italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;0.49, Pearson <italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;0.40), and the percentage area of hydrophobic patches (Spearman <italic toggle="yes">r</italic>&#8201;=&#8201;0.39, Pearson <italic toggle="yes">r</italic>&#8201;=&#8201;0.44) (<xref rid="f0005" ref-type="fig">Figure 5</xref> and Table S5).
<fig position="float" id="f0005" fig-type="figure" orientation="portrait"><label>Figure 5.</label><caption><p>Correlation of experimental colloidal stability (kD) with selected <italic toggle="yes">in silico</italic> surface descriptors. scatter plots illustrating relationships between experimental kD values and computed surface descriptors: a) positive patch area (pro_patch_pos_%), b) percentage area of negative surface patches (pro_patch_neg_%), and c) percentage area of hydrophobic surface patches (pro_patch_hyd_%).</p></caption><alt-text>Scatter plots showing correlations between experimental colloidal stability (kD values) and in silico surface descriptors for antibody constructs: (a) positive patch area (%), with Pearson r = 0.58 and Spearman r = 0.57; (b) negative patch area (%), with Pearson r = &#8722;0.40 and Spearman r = &#8722;0.49; and (c) hydrophobic patch area (%), with Pearson r = 0.44 and Spearman r = 0.39.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0005_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0005_PB.jpg"/></alternatives></fig></p><p>These findings are in good agreement with previous studies on conventional monoclonal antibodies, such as Mock et al.,<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup> who also identified surface charge patch descriptors as important predictors of colloidal stability. Additionally, Mock et al. observed a very strong correlation between sequence-based pI and kD (Spearman <italic toggle="yes">r</italic>&#8201;=&#8201;0.85), highlighting the general correlation and usefulness of pI for assessing colloidal stability and solution behavior. Specifically, Mock et al. reported correlations for complementary-determining region (CDR)-specific negative surface patches (pro_patch_cdr_neg_n, <italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;0.44), CDR-specific positive surface patches (pro_patch_cdr_pos_5, <italic toggle="yes">r</italic>&#8201;=&#8201;0.40), and global negative surface patches (pro_patch_neg, <italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;0.28). While Mock et al. reported absolute surface patch values due to their uniform antibody architecture and single-buffer measurements, and we focused our analysis on percentage-based descriptors to account for the varying sizes and domain compositions in our multispecific dataset, both studies found that higher positive surface patches and lower negative surface patches were associated with improved colloidal stability.</p><p>The absence of a single dominant correlation within our dataset aligns logically with the multifactorial nature of protein solution behavior. Colloidal stability is influenced by a combination of surface charge distribution, hydrophobicity, and potentially other molecular or environmental factors. These additional factors may include structural dynamics, specific buffer-antibody interactions, and variations in ionic strength, as discussed further below.</p><p>However, although each correlation is individually moderate, these descriptors can be holistically used to modulate and optimize colloidal stability of formulations for complex biotherapeutics formats. Even a modest increase in positively charged patches and/or a decrease in negatively charged or hydrophobic patches on the surface of the protein can significantly increase the kD value and decrease the risk of protein self-interaction.</p></sec></sec><sec disp-level="2" id="s0002-s2006"><title>Engineered variants show favorable pH sensitivity properties, indicating stability during viral inactivation processes</title><p>pH sensitivity testing is essential for evaluating the stability and safety of therapeutic antibodies, particularly regarding their susceptibility to viral inactivation (VI). The risk of viral contamination in biotechnology products derived from cell lines is significant and must be minimized due to potential clinical consequences. In biopharmaceutical manufacturing, viral inactivation is commonly achieved by exposure to extreme pH conditions (typically around pH 3.5 or pH 11.0) or through heat treatment. Understanding antibody stability under these harsh conditions is essential to ensure structural integrity and functional preservation during manufacturing.</p><p>pH sensitivity testing is routinely integrated into our general developability and manufacturability assessment workflow. Following the established protocol detailed in the Methods section, all constructs were normalized to a concentration of 2&#8201;mg/ml in histidine buffer pH 5.5, followed by buffer exchange to pH 3.5 or 11.0. Samples were incubated for 30&#8201;minutes at these extreme pH conditions and subsequently returned to the original buffer. Analytical SEC results and material recovery rates for all samples are summarized in <xref rid="t0003" ref-type="table">Table 3</xref>.<table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>Results from pH sensitivity testing mimicking viral inactivation (VI) procedures during biomolecule manufacturing.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" char="." colspan="1" rowspan="1">pH 5.5</th><th colspan="3" align="center" char="." rowspan="1">low pH (pH 3.5) hold<hr/></th><th colspan="3" align="center" char="." rowspan="1">high pH (pH 11.0) hold<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">Name</th><th align="center" char="." colspan="1" rowspan="1">Monomer SEC [%] pre-VI</th><th align="center" char="." colspan="1" rowspan="1">Recovery [%]</th><th align="center" colspan="1" rowspan="1">Monomer SEC [%] post-VI</th><th align="center" colspan="1" rowspan="1">&#916; Monomer SEC [%]</th><th align="center" char="." colspan="1" rowspan="1">Recovery [%]</th><th align="center" colspan="1" rowspan="1">Monomer SEC [%] post-VI</th><th align="center" colspan="1" rowspan="1">&#916; Monomer SEC [%]</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Fc-VHH<sub>H</sub></td><td align="char" char="." colspan="1" rowspan="1">97.8</td><td align="char" char="." colspan="1" rowspan="1">83.6</td><td align="center" colspan="1" rowspan="1">98.7</td><td align="center" colspan="1" rowspan="1">0.9</td><td align="char" char="." colspan="1" rowspan="1">84.9</td><td align="center" colspan="1" rowspan="1">98.9</td><td align="center" colspan="1" rowspan="1">1.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Fc-VHH<sub>M</sub></td><td align="char" char="." colspan="1" rowspan="1">95.3</td><td align="char" char="." colspan="1" rowspan="1">85.6</td><td align="center" colspan="1" rowspan="1">95.7</td><td align="center" colspan="1" rowspan="1">0.4</td><td align="char" char="." colspan="1" rowspan="1">83.3</td><td align="center" colspan="1" rowspan="1">94.7</td><td align="center" colspan="1" rowspan="1">&#8722;0.6</td></tr><tr><td align="left" colspan="1" rowspan="1">Fc-VHH<sub>L</sub></td><td align="char" char="." colspan="1" rowspan="1">99.5</td><td align="char" char="." colspan="1" rowspan="1">89.0</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">0.5</td><td align="char" char="." colspan="1" rowspan="1">90.6</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">0.5</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc-VHH<sub>H</sub></td><td align="char" char="." colspan="1" rowspan="1">98.7</td><td align="char" char="." colspan="1" rowspan="1">86.9</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">1.3</td><td align="char" char="." colspan="1" rowspan="1">83.2</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">1.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc-VHH<sub>M</sub></td><td align="char" char="." colspan="1" rowspan="1">98.0</td><td align="char" char="." colspan="1" rowspan="1">86.3</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">2.0</td><td align="char" char="." colspan="1" rowspan="1">82.9</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">2.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc-VHH<sub>L</sub></td><td align="char" char="." colspan="1" rowspan="1">97.8</td><td align="char" char="." colspan="1" rowspan="1">90.5</td><td align="center" colspan="1" rowspan="1">98.5</td><td align="center" colspan="1" rowspan="1">0.8</td><td align="char" char="." colspan="1" rowspan="1">83.7</td><td align="center" colspan="1" rowspan="1">98.6</td><td align="center" colspan="1" rowspan="1">0.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc-VHH<sub>H</sub></td><td align="char" char="." colspan="1" rowspan="1">97.3</td><td align="char" char="." colspan="1" rowspan="1">86.7</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">2.7</td><td align="char" char="." colspan="1" rowspan="1">84.3</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">2.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc-VHH<sub>M</sub></td><td align="char" char="." colspan="1" rowspan="1">97.9</td><td align="char" char="." colspan="1" rowspan="1">87.9</td><td align="center" colspan="1" rowspan="1">98.8</td><td align="center" colspan="1" rowspan="1">0.9</td><td align="char" char="." colspan="1" rowspan="1">84.4</td><td align="center" colspan="1" rowspan="1">98.9</td><td align="center" colspan="1" rowspan="1">1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc-VHH<sub>L</sub></td><td align="char" char="." colspan="1" rowspan="1">97.4</td><td align="char" char="." colspan="1" rowspan="1">82.6</td><td align="center" colspan="1" rowspan="1">99.0</td><td align="center" colspan="1" rowspan="1">1.6</td><td align="char" char="." colspan="1" rowspan="1">88.9</td><td align="center" colspan="1" rowspan="1">98.6</td><td align="center" colspan="1" rowspan="1">1.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>L</sub>-Fc-VHH<sub>H</sub></td><td align="char" char="." colspan="1" rowspan="1">96.2</td><td align="char" char="." colspan="1" rowspan="1">80.1</td><td align="center" colspan="1" rowspan="1">99.3</td><td align="center" colspan="1" rowspan="1">3.1</td><td align="char" char="." colspan="1" rowspan="1">78.4</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">3.8</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>L</sub>-Fc-VHH<sub>M</sub></td><td align="char" char="." colspan="1" rowspan="1">97.4</td><td align="char" char="." colspan="1" rowspan="1">118.4</td><td align="center" colspan="1" rowspan="1">98.6</td><td align="center" colspan="1" rowspan="1">1.2</td><td align="char" char="." colspan="1" rowspan="1">94.9</td><td align="center" colspan="1" rowspan="1">99.4</td><td align="center" colspan="1" rowspan="1">2.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>L</sub>-Fc-VHH<sub>L</sub></td><td align="char" char="." colspan="1" rowspan="1">95.2</td><td align="char" char="." colspan="1" rowspan="1">33.3</td><td align="center" colspan="1" rowspan="1">n.a.</td><td align="center" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">29.2</td><td align="center" colspan="1" rowspan="1">n.a.</td><td align="center" colspan="1" rowspan="1">n.a.</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc</td><td align="char" char="." colspan="1" rowspan="1">99.1</td><td align="char" char="." colspan="1" rowspan="1">82.1</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">1.0</td><td align="char" char="." colspan="1" rowspan="1">84.4</td><td align="center" colspan="1" rowspan="1">100.0</td><td align="center" colspan="1" rowspan="1">1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc</td><td align="char" char="." colspan="1" rowspan="1">96.9</td><td align="char" char="." colspan="1" rowspan="1">90.0</td><td align="center" colspan="1" rowspan="1">98.2</td><td align="center" colspan="1" rowspan="1">1.3</td><td align="char" char="." colspan="1" rowspan="1">91.3</td><td align="center" colspan="1" rowspan="1">98.4</td><td align="center" colspan="1" rowspan="1">1.5</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>L</sub>-Fc</td><td align="char" char="." colspan="1" rowspan="1">96.6</td><td align="char" char="." colspan="1" rowspan="1">86.3</td><td align="center" colspan="1" rowspan="1">98.2</td><td align="center" colspan="1" rowspan="1">1.6</td><td align="char" char="." colspan="1" rowspan="1">85.0</td><td align="center" colspan="1" rowspan="1">97.7</td><td align="center" colspan="1" rowspan="1">1.1</td></tr></tbody></table><table-wrap-foot><fn id="tfn0004"><p>n.a.: not available (due to insufficient recovery)</p></fn></table-wrap-foot></table-wrap></p><p>Overall, all constructs except Fab<sub>L</sub>-Fc-VHH<sub>L</sub> showed robust resistance to extreme pH conditions and the rebuffering process at 2&#8201;mg/ml, as evidenced by minimal changes in monomer content (&#916; Monomer % SEC close to zero) and high recovery rates (~80&#8211;90%). Positive &#916; Monomer % SEC values reflect either a reduction in aggregate content or inherent measurement variability, whereas negative values indicate increased aggregation triggered by pH stress. Notably, the Fab<sub>L</sub>-Fc-VHH<sub>L</sub> variant exhibited significantly reduced recovery (~30%), likely due to precipitation, filtration losses, or absorption to the buffer exchange resin.</p><p>Overall, these findings demonstrate that most engineered variants, including the parental and optimized constructs (Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>H</sub>-Fc-VHH<sub>M</sub>), maintain robust stability under the applied extreme pH conditions at the given concentrations (2&#8201;mg/ml), highlighting their suitability for manufacturing processes involving viral inactivation steps.</p></sec><sec disp-level="2" id="s0002-s2007"><title>Optimized bispecific constructs show improved viscosity properties</title><p>Finally, to investigate the impact of charge engineering on viscosity at high concentrations, we concentrated samples in histidine buffers at pH 5.5 and 6.5 and monitored the concentration process to compare the behavior of the starting molecule Fab<sub>M</sub>-Fc-VHH<sub>L</sub> and the best optimized constructs Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>H</sub>-Fc-VHH<sub>M</sub>. Due to limited material availability after mid-scale production, we focused our viscosity analysis on histidine buffers at pH 5.5 and 6.5, which represent commonly used formulation conditions in commercial antibody therapeutics. As shown in <xref rid="f0006" ref-type="fig">Figure 6a</xref>, the optimized constructs demonstrated significantly faster up-concentration kinetics compared to the starting molecule, highlighting their enhanced suitability for high-concentration formulations.
<fig position="float" id="f0006" fig-type="figure" orientation="portrait"><label>Figure 6.</label><caption><p>Up-concentration kinetics and viscosity properties of engineered constructs. a) up-concentration kinetics of the starting molecule Fab<sub>M</sub>-Fc-VHH<sub>L</sub> and optimized constructs Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>H</sub>-Fc-VHH<sub>M</sub> in histidine buffers at pH 5.5 and 6.5, showing significantly faster kinetics for the optimized constructs. b) viscosity measurements for constructs at 83 mg/mL, demonstrating improved solution behavior for the optimized constructs compared to Fab<sub>M</sub>-Fc-VHH<sub>L</sub>. Viscosity values are means of n replicate measurements: FabM-Fc-VHHL, <italic toggle="yes">n</italic>=2* (pH 5.5), <italic toggle="yes">n</italic>=1** (pH 6.5); FabH-Fc-VHHH and FabH-Fc-VHHM, <italic toggle="yes">n</italic>=3 (both pH values).</p></caption><alt-text>Two-panel figure showing (a) up-concentration kinetics for the starting molecule FabM-Fc-VHHL and optimized constructs FabH-Fc-VHHH and FabH-Fc-VHHM in histidine buffers at pH 5.5 and 6.5, highlighting faster kinetics for optimized constructs. (b) Bar chart of viscosity measurements at 83 mg/mL for the same constructs, demonstrating improved solution behavior for optimized constructs compared to FabM-Fc-VHHL. Viscosity values are means of replicate measurements, with notes on removed or limited data due to quality or material availability.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0006_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0006_PB.jpg"/></alternatives><attrib>*Third measurement removed due to poor quality data</attrib><attrib>**Single measurement due to low material availability</attrib></fig></p><p>While all other samples were successfully and rapidly concentrated to over 100&#8201;mg/mL without any changes in appearance, the starting molecule exhibited poor recovery and noticeable opalescence at pH 6.5. This further indicates compromised stability under these conditions and a pronounced tendency for self-interaction, which resulted in lower flux during filtration and material loss, potentially due to absorption to the filter and clogging (<xref rid="t0004" ref-type="table">Table 4</xref>).<table-wrap position="float" id="t0004" orientation="portrait"><label>Table 4.</label><caption><p>Results from generation of high concentration samples and viscosity measurements for the starting molecule and two optimized constructs.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" char="." rowspan="1">Recovery (%)<hr/></th><th colspan="2" align="center" char="." rowspan="1">c (mg/mL)<sup>a)</sup><hr/></th><th colspan="2" align="center" rowspan="1">Appearance<hr/></th><th colspan="2" align="center" char="." rowspan="1">Viscosity (cP)<sup>b)</sup><hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">Name</th><th align="center" char="." colspan="1" rowspan="1">pH 5.5</th><th align="center" char="." colspan="1" rowspan="1">pH 6.5</th><th align="center" char="." colspan="1" rowspan="1">pH 5.5</th><th align="center" char="." colspan="1" rowspan="1">pH 6.5</th><th align="center" colspan="1" rowspan="1">pH 5.5</th><th align="center" colspan="1" rowspan="1">pH 6.5</th><th align="center" char="." colspan="1" rowspan="1">pH 5.5</th><th align="center" char="." colspan="1" rowspan="1">pH 6.5</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Fab<sub>M</sub>-Fc-VHH<sub>L</sub></td><td align="char" char="." colspan="1" rowspan="1">72.0</td><td align="char" char="." colspan="1" rowspan="1">59.0</td><td align="char" char="." colspan="1" rowspan="1">119.3</td><td align="char" char="." colspan="1" rowspan="1">82.9</td><td align="left" colspan="1" rowspan="1">no VP<sup>c)</sup></td><td align="left" colspan="1" rowspan="1">opalescense</td><td align="char" char="." colspan="1" rowspan="1">7.8</td><td align="char" char="." colspan="1" rowspan="1">7.5</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc-VHH<sub>M</sub></td><td align="char" char="." colspan="1" rowspan="1">74.0</td><td align="char" char="." colspan="1" rowspan="1">71.0</td><td align="char" char="." colspan="1" rowspan="1">105.9</td><td align="char" char="." colspan="1" rowspan="1">133.4</td><td align="left" colspan="1" rowspan="1">no VP</td><td align="left" colspan="1" rowspan="1">no VP</td><td align="char" char="." colspan="1" rowspan="1">6.0</td><td align="char" char="." colspan="1" rowspan="1">5.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Fab<sub>H</sub>-Fc-VHH<sub>H</sub></td><td align="char" char="." colspan="1" rowspan="1">86.0</td><td align="char" char="." colspan="1" rowspan="1">85.0</td><td align="char" char="." colspan="1" rowspan="1">150.0</td><td align="char" char="." colspan="1" rowspan="1">119.1</td><td align="left" colspan="1" rowspan="1">no VP</td><td align="left" colspan="1" rowspan="1">no VP</td><td align="char" char="." colspan="1" rowspan="1">5.6</td><td align="char" char="." colspan="1" rowspan="1">5.1</td></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p><sup>a)</sup>concentration measured at the end of the up-concentration step</p></fn><fn id="tfn0006"><p><sup>b)</sup>viscosities were measured at 83&#8201;mg/mL to allow for a head-to-head comparison</p></fn><fn id="tfn0007"><p>VP&#8201;=&#8201;visible particles.</p></fn></table-wrap-foot></table-wrap></p><p><sup>c)</sup>For a direct head-to-head viscosity comparison, the concentration of Fab<sub>M</sub>-Fc-VHH<sub>L</sub> at pH 6.5 was limited to 83&#8201;mg/mL, and the other samples were diluted to match this concentration. Both optimized constructs showed improved viscosity profiles in both formulation buffers compared to the starting molecule. Specifically, Fab<sub>H</sub>-Fc-VHH<sub>H</sub> demonstrated the lowest viscosities at both pH 5.5 (5.6 cP) and pH 6.5 (5.1 cP), followed closely by Fab<sub>H</sub>-Fc-VHH<sub>M</sub> (6.0 cP at pH 5.5 and 5.3 cP at pH 6.5), whereas the starting molecule Fab<sub>M</sub>-Fc-VHH<sub>L</sub> exhibited higher viscosities (7.8 cP at pH 5.5 and 7.5 cP at pH 6.5) (<xref rid="f0006" ref-type="fig">Figure 6b</xref>, <xref rid="t0004" ref-type="table">Table 4</xref>).</p><p>These results strongly support our hypothesis that the charge asymmetries identified in Fab<sub>M</sub>-Fc-VHH<sub>L</sub> at pH 5.5 and 6.5 (<xref rid="t0001" ref-type="table">Table 1</xref>) trigger self-interactions. Importantly, these unfavorable interactions could be efficiently mitigated through targeted charge engineering of both Fab and VHH domains.</p><p>Consistent with this rationale, despite pH 6.5 being close to the pI of the VHH<sub>M</sub> domain, Fab<sub>H</sub>-Fc-VHH<sub>M</sub> showed lower viscosity under this condition. Comparison of computed versus experimental pI values (<xref rid="t0002" ref-type="table">Table 2</xref>, Figure S3) indicates that the computed pI of VHH<sub>M</sub> is slightly underestimated, meaning the actual net charge of VHH<sub>M</sub> at pH 6.5 may be somewhat more positive than predicted. As all domains (Fab, Fc, VHH) remain positively charged at this pH, there is no significant charge asymmetry within the molecule to promote attractive electrostatic-driven self-interactions. This supports the interpretation that the favorable viscosity profile results from the combination of strong electrostatic repulsion provided by the highly charged Fab<sub>H</sub> domain and the absence of charge asymmetry or attractive interactions involving VHH<sub>M</sub> or the Fc domain at this pH.</p><p>Furthermore, in line with the colloidal stability findings, Fab<sub>H</sub>-Fc-VHH<sub>H</sub> displayed even lower viscosities than Fab<sub>H</sub>-Fc-VHH<sub>M</sub>, confirming that enhanced electrostatic repulsive forces further improved solution behavior. Notably, and in full agreement with the colloidal stability results discussed earlier, all three molecules consistently exhibited lower viscosity in histidine buffer at pH 6.5 compared to pH 5.5, underscoring the complex interplay between buffer conditions, electrostatic interactions, and antibody solution properties.</p></sec></sec><sec disp-level="1" id="s0003"><title>Discussion</title><p>In this study, we successfully optimized the solution behavior of a bispecific IgG1-VHH antibody through rational charge engineering of both Fab and VHH domains, leading to significant improvements in colloidal stability and viscosity. By systematically combining high, intermediate, and low pI variants of both domains, we assessed colloidal stability, thermal stability, hydrophobicity, and pH sensitivity across a broad pH range. Two optimized constructs, Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>H</sub>-Fc-VHH<sub>M</sub>, demonstrated notably improved colloidal stability and viscosity compared to the initial molecule, Fab<sub>M</sub>-Fc-VHH<sub>L</sub>. Our findings indicate that balancing pI profiles and ensuring positively charged domains effectively mitigates charge asymmetries and reduces unfavorable self-interactions.</p><p>These results align closely with established insights for classical monospecific IgG1 antibodies, where poor solution behavior typically arises from attractive Fab &#8211; Fab or Fab &#8211; Fc interactions. Evidence from multiple studies<sup><xref rid="cit0027" ref-type="bibr">27</xref>,<xref rid="cit0028" ref-type="bibr">28</xref>,<xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0052" ref-type="bibr">52</xref></sup> shows that negatively charged Fv regions increase viscosity risk, probably via Fv &#8211; Fc interactions with positive Fc patches.<sup><xref rid="cit0054" ref-type="bibr">54</xref></sup> Consequently, in both mono- and multispecific antibodies, maintaining positively (or neutrally) charged variable domains at formulation pH should reduce this risk. Indeed, Gupta et al.<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup> previously recommended an optimal pI range of 7.5&#8211;9.0 for Fv regions of classical IgGs, which effectively balances colloidal stability and nonspecific binding. This pI range is slightly above that of Fc regions in typical IgG1-derived antibody constructs (~7.2), helping to reduce charge asymmetries and promoting positively charged domains in commonly used formulation buffers at pH&#8201;&#8804;&#8201;7 (e.g., Histidine at pH 5.5 to 6.5). While our dataset is limited relative to the broad universe of multispecific constructs, we suggest extending Gupta et al.&#8217;s recommendation to any variable domain (Fv, scFv, VHH) within multispecific antibodies. Engineering domain pI values to&#8201;&#8805;&#8201;7.5 appears generally beneficial for enhancing electrostatic repulsion and colloidal stability, particularly in acidic liquid formulations. In formulation buffers near or above the Fc pI (~7.2), the risk for Fc-mediated self-association may increase, especially if charge asymmetries between different domains (including the Fc domain) are present. However, it is crucial to consider that engineering excessively high charges into variable regions can lead to polyreactivity, where antibodies may bind nonspecifically to various targets, potentially compromising their therapeutic efficacy and safety.<sup><xref rid="cit0067" ref-type="bibr">67&#8211;71</xref></sup> While existing literature provides insights into the polyreactivity of classical antibodies, similar data specific to VHH domains in multispecific constructs remain sparse.<sup><xref rid="cit0072" ref-type="bibr">72</xref></sup> In particular, while an upper pI cutoff of 9.0&#160;has been proposed for Fv regions of monospecific antibodies to reduce the risk for polyreactivity,<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup> its applicability and implications for VHHs requires further investigation.</p><p>Colloidal stability remains a critical experimental predictor of antibody solution behavior, as demonstrated previously<sup><xref rid="cit0038" ref-type="bibr">38</xref></sup> and confirmed herein. However, experimental assessment requires substantial protein quantities (2&#8201;mg per condition in this study), often unavailable during early discovery phases. Alternative predictive assays (e.g., AC-SINS, CS-SINS, PEG solubility) offer high-throughput options at smaller scales, yet <italic toggle="yes">in silico</italic> tools uniquely enable evaluation and prioritization of variant sequences <italic toggle="yes">before</italic> experimental production and testing. Given the combinatorial complexity inherent in multispecific antibody design, incorporating a targeted pI range (~7.5&#8211;9.0) per variable domain as an additional selection or design criterion could pragmatically streamline early-phase paratope optimization, particularly when liquid formulations are desired in the candidate drug target profile.<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup> Importantly, while we propose domain pI as a practical early-stage design parameter, our data and analysis underscore that optimal solution behavior arises from the interplay of multiple molecular and environmental factors, including, but not limited to, surface charge distribution, hydrophobicity, local structural features, and buffer composition. Thus, per-domain pI should be considered as one component within a holistic, multi-parameter developability assessment, rather than as a stand-alone surrogate.</p><p>Despite the acknowledged complexity of protein solution behavior, it is noteworthy that pI, a simple, sequence-based descriptor, consistently emerges as one of the most predictive single parameters for colloidal stability and viscosity across different monospecific antibody datasets. In the comprehensive study by Mock et al.<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup> on 83 monospecific IgG1 antibodies measured in acetate buffer at pH 5.2, sequence-based pI (pro_pI_seq) showed the strongest correlation with kD among&#8201;&gt;&#8201;100 computed descriptors (Spearman <italic toggle="yes">r</italic>&#8201;=&#8201;0.85), outperforming all structure-based features. Similarly, Makowski et al.<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup> demonstrated that an Fv pI cutoff of&#8201;&gt;&#8201;6.3 achieved an area under the curve (AUC) of 0.87 for differentiating between low and high viscosity monospecific antibodies that were also measured in acetate buffer at pH 5.2. These findings underscore that while solution behavior is influenced by multiple factors, pI and charge capture fundamental electrostatic properties that are key for colloidal stability and viscosity, making it a valuable parameter for early-stage assessments.</p><p>While the assays used in this study are useful for assessing solution behavior relevant to solubility, formulatability, and several aspects of manufacturability, they do not address other aspects of multispecific antibody developability, such as binding specificity, functional activity, immunogenicity, expression yields, purification scalability, or pharmacokinetics. These aspects are beyond the scope of this study, which focuses on optimizing solution behavior. Further studies are necessary to address these broader developability attributes for multispecific antibodies.</p><p>Notwithstanding these promising results, our study has several limitations. We focused on a single bispecific architecture and a limited number of Fab and VHH variants, restricting broad generalizations. Additionally, domain charge and pI serve as pragmatic but simplified descriptors. Indeed, local charge distributions, domain and linker conformations, hydrophobicity, and intra-domain charge asymmetries (e.g., between VH and VL chains) can significantly influence solution behavior. For example, constructs Fab<sub>M</sub>-Fc-VHH<sub>H</sub> and Fab<sub>M</sub>-Fc-VHH<sub>M</sub> (computed pI values of 8.3 and 8.1, respectively) exhibited unexpectedly poor colloidal stability at pH 5.5 despite balanced and positive overall charges, underscoring the complexity beyond simple domain-level charge metrics. Similarly, the optimized constructs Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>H</sub>-Fc-VHH<sub>M</sub> displayed lower viscosity and better colloidal stability at pH 6.5 compared to 5.5, despite higher computed domain charges at lower pH. This discrepancy may be attributed to buffer-specific aspects, notably the positive charge of histidine&#8217;s imidazole group (pKa&#8201;=&#8201;6.0) at pH 5.5,<sup><xref rid="cit0074" ref-type="bibr">74</xref></sup> increasing ionic strength and potentially shielding electrostatic repulsion. At pH 6.5, histidine is predominantly neutral, reducing the solution&#8217;s ionic strength and possibly interacting with and shielding hydrophobic antibody surfaces,<sup><xref rid="cit0075" ref-type="bibr">75</xref></sup> thus enhancing colloidal stability. Furthermore, the solvation shell of the protein can influence viscosity. Proteins with higher net charge can bind additional layers of water, which in turn can impact its rheological behavior. Dedicated future studies exploring these buffer-specific interactions (including acetate, histidine, and TRIS buffers) would be valuable.</p><p>Additionally, our viscosity analysis was limited to histidine buffers at pH 5.5 and 6.5 due to material constraints, preventing a comprehensive assessment across all formulation conditions tested for colloidal stability. Viscosity measurements in acetate (pH 4.5) and TRIS (pH 8.0) buffers would further help distinguish whether the observed pH-dependent viscosity trends are buffer-specific or reflect broader electrostatic and structural effects, particularly for understanding cases where viscosity behavior near domain pI values deviates from predictions.</p><p>Moreover, multi-parameter optimization remains inherently challenging. While charge engineering can improve solution behavior, it may inadvertently introduce polyreactivity risks<sup><xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0072" ref-type="bibr">72</xref></sup> or negatively impact binding affinity. Indeed, we observed that pI-increasing modifications within the VHH CDR3 of our bispecific NKCE reduced NKp30 binding affinity (see Supplemental Materials for details). Typically, VHH domains require humanization<sup><xref rid="cit0076" ref-type="bibr">76&#8211;78</xref></sup> and sequence optimization<sup><xref rid="cit0079" ref-type="bibr">79&#8211;81</xref></sup> unless derived from a humanized library.<sup><xref rid="cit0082" ref-type="bibr">82</xref>,<xref rid="cit0083" ref-type="bibr">83</xref></sup> Similarly, optimization requirements for Fabs and conventional antibodies depend strongly on their source. Antibodies derived from human or humanized repertoires often require optimization of their physico-chemical properties, immunogenicity, and post-translational modifications (PTMs); those from animal immunization additionally need humanization; and those from synthetic libraries frequently have to undergo affinity maturation. Pragmatically, incorporating pI considerations as an additional parameter during these routine optimization steps could enhance solution behavior. One potential strategy to optimize the pI profile while preserving binding affinity involves modifying charge profiles through alternative human framework sequences rather than CDR modifications, an approach previously applied successfully to improve pharmacokinetics without affinity trade-offs.<sup><xref rid="cit0084" ref-type="bibr">84</xref></sup></p><p>In conclusion, our findings demonstrate that rational charge and pI engineering can effectively reduce electrostatic-driven self-interaction, thereby improving the colloidal stability and viscosity of multispecific antibodies in acidic formulation buffers. We recommend an optimal variable domain pI range of approximately 7.5&#8211;9.0 specifically to reduce electrostatic self-interaction in acidic formulations (<xref rid="f0007" ref-type="fig">Figure 7</xref>). While pI and charge descriptors provide a pragmatic early-stage strategy to mitigate risks associated with electrostatic self-association, we recognize that antibody solution behavior is inherently multifactorial. Other physicochemical attributes, such as conformational stability, hydrophobicity, linker design and format architecture, are governed by additional, partly independent determinants and may require case-specific screening and optimization. Future research extending these insights across diverse multispecific antibody formats and systematically exploring additional molecular factors, including linker design, as well as formulation parameters, will further refine predictive models and support the rational design of next-generation antibody therapeutics.
<fig position="float" id="f0007" fig-type="figure" orientation="portrait"><label>Figure 7.</label><caption><p>Schematic illustration of the proposed optimal domain pI range (~7.5&#8211;9.0) for reducing electrostatic-driven self-interaction in multispecific antibodies. Aligning domain pI values within this slightly basic range promotes positively charged surface patches across domains, thereby reducing electrostatic-driven self-association in acidic formulation buffers. In contrast, significant charge asymmetries between domains can increase the risk of electrostatically driven interactions and aggregation. This figure focuses specifically on the electrostatic aspect of solution behavior; other developability attributes may be influenced by additional, independent factors. Figure generated with biorender (<ext-link xlink:href="https://www.biorender.com" ext-link-type="uri">https://www.biorender.com</ext-link>).</p></caption><alt-text>Schematic illustration of the proposed optimal domain pI range (~7.5&#8211;9.0) for reducing electrostatic-driven self-interaction in multispecific antibodies. Displays charge distribution across domains in acidic formulations, promoting positively charged surface patches to reduce self-association risks. Highlights increased risk of aggregation with significant charge asymmetries. Focuses on electrostatic solution behavior; other developability attributes are not depicted.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0007_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2553622_F0007_PB.jpg"/></alternatives></fig></p></sec><sec disp-level="1" id="s0004"><title>Materials and methods</title><sec disp-level="2" id="s0004-s2001"><title>Protein expression and purification</title><p>Antibodies were transiently expressed from ExpiCHO&#8482; cells (Thermo Fisher Scientific) following a 12-days protocol at 500&#8211;3000&#8201;mL scale according to the manufacturer&#8217;s instructions (Max Titer Protocol). The cultivation protocol included a temperature shift from 37.0&#176;C to 32.0&#176;C after addition of ExpiFectamine CHO enhancer and first ExpiCHO feed at day 1 while incubating at 5% CO<sub>2</sub> and 130 rpm. Plasmids for transfections (pTT5 backbone) were used at 1.0&#8201;mg/L and were mixed 1:1 for heavy/light chain containing IgG constructs. Antibody-containing supernatants were harvested by centrifugation at 5200&#8201;&#215;&#8201;g for 60&#8201;min and afterward 0.2&#8201;&#181;m sterile filtered. Protein purification was performed by affinity capture on Protein A resin (MabSelect SuRe, 25&#8201;mL) and proteins were eluted with 100&#8201;mM acetic acid (pH 3.2) at a flow rate of 10&#8201;mL/min using an &#196;KTA chromatography system, followed by neutralization. Protein purity was determined at 214&#8201;nm by analytical SEC on a TSKgel SW3000 column (2&#8201;&#181;m, 4.6&#8201;&#215;&#8201;300&#8201;mm, Tosoh Bioscience) using an Agilent HPLC system. 7.5&#8201;&#181;g protein per sample was injected and run at a flow rate of 0.35&#8201;mL/min using 50&#8201;mM sodium phosphate, 0.4&#8201;M NaClO4 pH 6.3 as mobile phase. Antibodies were afterward polished by preparative SEC using HiLoad Superdex 200 pg columns (Cytiva) using 20&#8201;mM Histidine, 150&#8201;mM NaCl pH 5.5&#8211;7.5. Samples were subsequently desalted into 20&#8201;mM histidine, 8% trehalose (pH 5.5) using HiPrep 26/10 Desalting Columns (Cytiva), sterile-filtered through 0.2&#8201;&#181;m filters, flash-frozen in liquid nitrogen, and stored at&#8201;&#8722;&#8201;80&#176;C until further use. Final SEC protein purity was determined after one freeze/thaw cycle.</p></sec><sec disp-level="2" id="s0004-s2002"><title>Generation of structural models</title><p>To create structural models of the full-length IgGs and VHHs, we utilized the antibody modeling tool in the MOE software<sup><xref rid="cit0066" ref-type="bibr">66</xref></sup> with a default Amber10:EHT force field. Solvation was incorporated using the Generalized Born implicit model, with internal and external dielectric values set to 4 and 80, respectively. The non-bonded interaction tapered to zero between 10 and 12 &#197;.</p><p>Different architectures of the bispecific IgG-VHH and monospecific Fc-VHH control constructs were generated by adding linkers via MOE&#8217;s protein builder, followed by a conformational search of the linker via MOE&#8217;s linker modeler. The final structures were energy minimized to a root mean square gradient threshold of less than 10<sup>&#8722;3</sup> kcal/mol/&#197;<sup>2</sup>. All variants were prepared under four distinct conditions designed to replicate the formulation ranges experimentally assessed: 1) pH 4.5 with 7&#8201;mM ionic strength, 2) pH 5.5 with 15&#8201;mM ionic strength, 3) pH 6.5 with 5&#8201;mM ionic strength, and 4) pH 8.0 with 5&#8201;mM ionic strength. Ionic strengths were estimated based on the respective buffers used in the experiments. The protonation state was determined using the Protonate 3D function in MOE. Visualization of 3D structures was performed with PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schr&#246;dinger, LLC.).<sup><xref rid="cit0083" ref-type="bibr">83</xref></sup></p></sec><sec disp-level="2" id="s0004-s2003"><title>In silico protein properties and correlation workflow</title><p>Sequence-based isoelectric points and charges at various pH values were calculated using the Henderson-Hasselbalch equation, implemented through the ProteinAnalysis utility available in the Biopython library.<sup><xref rid="cit0085" ref-type="bibr">85</xref></sup></p><p>For all structure-based molecular descriptors, protein properties were calculated in MOE using the structural models from the four pH and ionic strength conditions (a complete list is provided in Figure S5 and Table S5). The pH value was included as an additional descriptor. To identify which protein descriptors were most highly correlated with the experimental properties, the following workflow was applied: 1) Descriptors with a Spearman correlation coefficient exceeding 0.75 were removed to reduce multicollinearity; 2) For each experimental property, any missing experimental data point led to removal of the corresponding computational data. Moreover, for HIC values, measured under a single experimental condition, only the descriptors computed at pH 6.5 were used; and 3) The Spearman correlation coefficient of each computational descriptor to the target experimental variable was determined, and only descriptors with correlations higher than <inline-formula id="ilm0001"><alternatives><inline-graphic xlink:href="KMAB_A_2553622_ILM0001.jpg"/><mml:math id="MATH0001"><mml:mn>2</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msqrt><mml:mi mathvariant="italic">n</mml:mi></mml:msqrt></mml:math></alternatives></inline-formula> (where <italic toggle="yes">n</italic> is the total number of samples) were retained (Figures S6-S10). Moreover, an agglomerative hierarchical clustering in SciPy with default parameters was applied to cluster the most correlated descriptors in groups, which is especially useful for further consolidating descriptors that are more correlated, thus aiding in reducing redundant predictors (Figure S11).</p></sec><sec disp-level="2" id="s0004-s2004"><title>Thermal stability determination</title><p>The thermal stability of 15 antibody constructs was analyzed using nanoDSF using Prometheus Panta (NanoTemper Technologies). Measurements were conducted at a concentration of 1&#8201;mg/ml in four different buffers: 20&#8201;mM Acetate pH 4.5, 20&#8201;mM Histidine pH 5.5, 20&#8201;mM Histidine pH 6.5 and 20&#8201;mM TRIS pH 8.0. Each sample was measured in duplicate. A linear thermal gradient from 25&#176;C to 95&#176;C was applied with a ramp rate of 1&#176;C/minute while recording fluorescence signals at 350&#8201;nm and 330&#8201;nm. The resulting melting curves allowed for the determination of the melting temperature (Tm) and onset temperature (Tonset) for each construct. Data were analyzed using the PR.Panta analysis software.</p></sec><sec disp-level="2" id="s0004-s2005"><title>Hydrophobic interaction chromatography</title><p>HIC was performed to assess the hydrophobicity of selected antibody constructs. Each sample (1&#8201;mg/ml) was prepared by diluting 1:1 with 2&#8201;M ammonium sulfate (Merck KGaA) and then 20&#8201;&#181;g was injected onto a TSKgel Butyl-NPR column (2.5&#8201;&#181;m, 4.6&#8201;mm ID&#8201;&#215;&#8201;100&#8201;mm, Tosoh Bioscience) using an Agilent HPLC 1260 Infinity system set to a flow rate of 0.5&#8201;mL/min. The elution was carried out using a linear gradient of two mobile phases over 15&#8201;minutes at 25&#176;C: Mobile phase A consisted of 1.2&#8201;M ammonium sulfate in 1x phosphate-buffered saline (PBS) at pH 6.5, while Mobile Phase B comprised 50% methanol in 0.1x PBS at pH 8.4. The retention times were recorded at 214&#8201;nm and the data was analyzed to determine the relative hydrophobicity of each construct by using anti-PD-L1 antibody avelumab as well as anti-EGFR antibody cetuximab (Erbitux&#174;) as hydrophobicity standards.</p></sec><sec disp-level="2" id="s0004-s2006"><title>Colloidal stability determination</title><p>The colloidal stability (kD, diffusion interaction parameter) for the different antibody constructs was determined by DLS using DynaPro Plate Reader III (Wyatt). All molecules were measured in four different formulation buffers: 20&#8201;mM Acetate pH 4.5, 20&#8201;mM Histidine pH 5.5, 20&#8201;mM Histidine pH 6.5 and 20&#8201;mM TRIS pH 8.0. A dilution series with four different concentrations (4&#8201;mg/ml, 2.8&#8201;mg/ml, 1.96&#8201;mg/ml, and 1.372&#8201;mg/ml) was prepared for the analysis by using a TECAN Fluent liquid handler with a final volume of 25&#8201;&#181;l for each well of a 384-well plate. All samples were measured in triplicates with a DLS acquisition time of 5&#8201;seconds and 5 repetitions for each well. Measurements were performed at 25&#176;C. Raw data were analyzed using MS Excel and kD values calculated by using following formular: k<sub>D</sub> [ml/g]&#8201;=&#8201;slope/intercept of a linear regression curve from a plot correlating the diffusion coefficient [cm<sup>2</sup>/s] with the protein concentration [g/ml]).</p></sec><sec disp-level="2" id="s0004-s2007"><title>Isoelectric point determination</title><p>The apparent isoelectric points (pIs) of the different antibody constructs were determined using the Maurice C system (ProteinSimple, Bio-Techne) with a separation method specifically tailored for this set. FabL-Fc-VHHL and FabH-Fc-VHHH were selected for method development, representing a broad range of calculated pI values. Initial experiments conducted without urea and SimpleSol resulted in significant aggregation within the capillary. To address this issue, either 4&#8201;M urea or 40% SimpleSol was incorporated into the MasterMix, with each condition favoring the separation of one of the antibodies. Ultimately, the complete sample set was analyzed using a combination of 2&#8201;M urea and 20% SimpleSol, which resulted in optimal overall separation.</p><p>Samples were pre-diluted in MilliQ purified water to yield a concentration of 0.2&#8201;mg/mL after dilution with the MasterMix. The final MasterMix comprised the following components (concentrations refer to the final sample solution): 35% methyl cellulose (ProteinSimple), 10&#8201;mM arginine (Merck KGaA), 2&#8201;M urea (Merck KGaA), 20% SimpleSol (ProteinSimple), 4% Pharmalyte 3&#8211;10 (Cytiva), and 2% pI markers (4.05 and 9.99; ProteinSimple). The applied voltage conditions were 1500&#8201;V for 1&#8201;minute, followed by 3000&#8201;V for 7&#8201;minutes. Data analysis was performed using the Compass for icIEF software from ProteinSimple/Bio-Techne. Per sample, experimental (<italic toggle="yes">n</italic>&#8201;=&#8201;2 aliquots prepared separately) as well as technical (<italic toggle="yes">n</italic>&#8201;=&#8201;2 injections from the same preparation) replicates were performed.</p></sec><sec disp-level="2" id="s0004-s2008"><title>pH sensitivity measurements</title><p>The pH sensitivity of the different antibody constructs was evaluated by incubating the samples at low and high pH followed by rebuffering to starting pH and analyzing increase of aggregation (decreasing % monomer) using SEC. First, each sample was diluted to a concentration of 2&#8201;mg/ml in 20&#8201;mM Histidine 8% Trehalose pH 5.5. Monomer content (Monomer % pre-VI) of each diluted sample was determined by SEC HPLC using a TSKgel UP-SW3000 column (4.6&#8201;mm ID x 30&#8201;cm L) with a buffer of 50&#8201;mM sodium phosphate 0.4&#8201;M sodium perchlorate pH 6.3 at 0.35&#8201;ml/min. Protein concentrations were confirmed by A280 measurement using a NanoDrop UV-VIS spectrophotometer (Thermo Scientific) for calculating overall recovery. The samples were then buffer exchanged into two different buffers: low pH buffer consisting of 55&#8201;mM Tris-Acetate at pH 3.5 and high pH buffer containing 125&#8201;mM Glycine at pH 11 using a ExpiCHO&#8482; Spin Desalting Plate with 96 wells (Thermo Scientific). The samples were afterward incubated at room temperature in those buffers for 30&#8201;minutes before being rebuffered into the starting buffer again followed by a filtration step using a 0.22&#8201;&#181;m PES filter plate. After this procedure, the final protein concentration of all samples was measured by A280 for calculating the recovery and levels of aggregates were investigated by SEC (Monomer % post-VI).</p></sec><sec disp-level="2" id="s0004-s2009"><title>Generation of high concentration samples and viscosity measurements</title><p>The starting molecule, Fab<sub>M</sub>-Fc-VHHL, and the optimized constructs, Fab<sub>H</sub>-Fc-VHH<sub>H</sub> and Fab<sub>H</sub>-Fc-VHH<sub>M</sub>, were buffer-exchanged using Zeba&#8482; Spin Desalting columns (Thermo Scientific) into two different formulation buffers: 20&#8201;mM Histidine at pH 5.5 and 20&#8201;mM histidine at pH 6.5. The final protein concentration of all samples was measured at A280 using a Stunner plate reader (Unchained Lab). The samples were then concentrated to a target concentration of &#8805;100&#8201;mg/mL (9-11x) using Vivaspin&#174; 30 kDa PES ultrafiltration centrifugal concentrators (Sartorius). The final protein concentration and volume of all samples were measured for recovery calculations. The progress of the concentration process was monitored, and the concentration factor was calculated at regular time intervals, extrapolated from the volume reduction observed during the concentration step. Up-concentration kinetic curves were generated by plotting the concentration factor against time (in minutes) to gain insights into the differences in behavior among antibodies during the concentration step. The last point of the curve corresponds to the ratio of the measured final concentration to the initial concentration. Due to limited material availability and significant protein loss during concentration of the starting Fab<sub>M</sub>-Fc-VHH<sub>L</sub>, all samples were diluted to the final concentration of 83&#8201;mg/mL for a head-to-head comparison of viscosity. The viscosity of high concentration antibody solutions was measured in triplicate using a Honeybun microvolume viscometer (Unchained Lab). For Fab<sub>M</sub>-Fc-VHH<sub>L</sub> in histidine at pH 5.5 and pH 6.5, viscosity measurements were conducted in duplicate and monoplicate, respectively, due to limited material availability. All measurements were performed in low volume mode at 25&#176;C.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM1025" position="float" content-type="local-data" orientation="portrait"><caption><title>SI_Multispecifics_revised01.docx</title></caption><media xlink:href="KMAB_A_2553622_SM1025.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM1024" position="float" content-type="local-data" orientation="portrait"><caption><title>sequences.txt</title></caption><media xlink:href="KMAB_A_2553622_SM1024.txt" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>We thank Achim D&#246;rner, J&#246;rg Plaschke and Markus Fleischer for coordinating protein production at our CRO in India (Syngene). We also thank Sapir Peled and Nicolas Rasche for carefully reading the manuscript and providing valuable comments.</p></ack><sec sec-type="COI-statement" disp-level="1" id="s0005"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec sec-type="data-availability" disp-level="1" id="s0006"><title>Data availability statement</title><p>This study includes no data deposited in external repositories.</p></sec><sec sec-type="supplementary-material" disp-level="1" id="s0007"><title>Supplementary material</title><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="https://doi.org/10.1080/19420862.2025.2553622" ext-link-type="uri">https://doi.org/10.1080/19420862.2025.2553622</ext-link></p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brinkmann</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Kontermann</surname><given-names>RE.</given-names></string-name></person-group><article-title>Bispecific antibodies</article-title>. <source>Science</source>. <year>2021</year>;<volume>372</volume>(<issue>6545</issue>):<fpage>916</fpage>&#8211;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.abg1209</pub-id>.<pub-id pub-id-type="pmid">34045345</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Keri</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Nishikawa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Garces</surname><given-names>F.</given-names></string-name></person-group><article-title>Next generation of multispecific antibody engineering</article-title>. <source>Antibody Ther</source>. <year>2024</year>;<volume>7</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1093/abt/tbad027</pub-id>.<pub-id pub-id-type="pmcid">PMC10791046</pub-id><pub-id pub-id-type="pmid">38235376</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klein</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Brinkmann</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Reichert</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Kontermann</surname><given-names>RE</given-names></string-name></person-group>. <article-title>The present and future of bispecific antibodies for cancer therapy</article-title>. <source>Nat Rev Drug Discov</source>. <year>2024</year>;<volume>23</volume>(<issue>4</issue>):<fpage>301</fpage>&#8211;<lpage>319</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41573-024-00896-6</pub-id>.<pub-id pub-id-type="pmid">38448606</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Niquille</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Fitzgerald</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Gera</surname><given-names>N</given-names></string-name></person-group>. <article-title>Biparatopic antibodies: therapeutic applications and prospects</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2310890</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2310890</pub-id>.<pub-id pub-id-type="pmid">38439551</pub-id><pub-id pub-id-type="pmcid">PMC10936611</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Surowka</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>C</given-names></string-name></person-group>. <article-title>A pivotal decade for bispecific antibodies?</article-title><source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2321635</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2321635</pub-id>.<pub-id pub-id-type="pmid">38465614</pub-id><pub-id pub-id-type="pmcid">PMC10936642</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chanier</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chames</surname><given-names>P</given-names></string-name></person-group>. <article-title>Nanobody engineering: toward next generation immunotherapies and immunoimaging of cancer</article-title>. <source>Antibodies</source>. <year>2019</year>;<volume>8</volume>(<issue>1</issue>):<fpage>13</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antib8010013</pub-id>.<pub-id pub-id-type="pmid">31544819</pub-id><pub-id pub-id-type="pmcid">PMC6640690</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>K&#246;nning</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zielonka</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grzeschik</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Empting</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Valldorf</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Krah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schr&#246;ter</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sellmann</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hock</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kolmar</surname><given-names>H</given-names></string-name></person-group>. <article-title>Camelid and shark single domain antibodies: structural features and therapeutic potential</article-title>. <source>Curr Opin Struct Biol</source>. <year>2017</year>;<volume>45</volume>:<fpage>10</fpage>&#8211;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.sbi.2016.10.019</pub-id>.<pub-id pub-id-type="pmid">27865111</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lipinski</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Unmuth</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Arras</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Endruszeit</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Becker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>R&#246;del</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Scheller</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pudewell</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Floss</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Krah</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Taming interleukin-12: engineering of bispecific antibody-based IL-12 mimetics with biased agonism capacities</article-title>. <source>Protein Sci</source>. <year>2025</year>;<volume>34</volume>(<issue>3</issue>):<fpage>e70072</fpage>. doi: <pub-id pub-id-type="doi">10.1002/pro.70072</pub-id>.<pub-id pub-id-type="pmid">39981925</pub-id><pub-id pub-id-type="pmcid">PMC11843475</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lipinski</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Unmuth</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Arras</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Becker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bauer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Toleikis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Krah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Doerner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yanakieva</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Boje</surname><given-names>AS</given-names></string-name>, et al</person-group>. <article-title>Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2236265</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2236265</pub-id>.<pub-id pub-id-type="pmid">37469014</pub-id><pub-id pub-id-type="pmcid">PMC10361135</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lipinski</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Arras</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pekar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Klewinghaus</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Boje</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Krah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zimmermann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Klausz</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Peipp</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Siegmund</surname><given-names>V</given-names></string-name>, et al</person-group>. <article-title>Nkp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats</article-title>. <source>Protein Sci</source>. <year>2023</year>;<volume>32</volume>(<issue>3</issue>):<fpage>e4593</fpage>. doi: <pub-id pub-id-type="doi">10.1002/pro.4593</pub-id>.<pub-id pub-id-type="pmid">36775946</pub-id><pub-id pub-id-type="pmcid">PMC9951198</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mullin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McClory</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Haynes</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Grace</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>van Heeke</surname><given-names>G</given-names></string-name></person-group>. <article-title>Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2341443</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2341443</pub-id>.<pub-id pub-id-type="pmid">38666503</pub-id><pub-id pub-id-type="pmcid">PMC11057648</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pekar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Busch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Valldorf</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hinz</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Toleikis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Krah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zielonka</surname><given-names>S</given-names></string-name></person-group>. <article-title>Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform</article-title>. <source>MAbs</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1812210</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2020.1812210</pub-id>.<pub-id pub-id-type="pmid">32887531</pub-id><pub-id pub-id-type="pmcid">PMC7531565</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boje</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Pekar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Koep</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lipinski</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rabinovich</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Evers</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gehlert</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Krohn</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Krah</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2315640</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2315640</pub-id>.<pub-id pub-id-type="pmid">38372053</pub-id><pub-id pub-id-type="pmcid">PMC10877975</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amash</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Volkers</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Farber</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Griffin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Davison</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tonikian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yamniuk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barnhart</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname><given-names>T</given-names></string-name></person-group>. <article-title>Developability considerations for bispecific and multispecific antibodies</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2394229</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2394229</pub-id>.<pub-id pub-id-type="pmid">39189686</pub-id><pub-id pub-id-type="pmcid">PMC11352713</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Condado-Morales</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Dingfelder</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Waibel</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Turnbull</surname><given-names>OM</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Rose Bjelke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nedergaard Grell</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bennet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hummer</surname><given-names>AM</given-names></string-name>, et al</person-group>. <article-title>A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2403156</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2403156</pub-id>.<pub-id pub-id-type="pmid">39364796</pub-id><pub-id pub-id-type="pmcid">PMC11457596</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fern&#225;ndez-Quintero</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Ljungars</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Waibl</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Greiff</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Gj&#248;lberg</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Jenkins</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Voldborg</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Grav</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Assessing developability early in the discovery process for novel biologics</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2171248</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2171248</pub-id>.<pub-id pub-id-type="pmid">36823021</pub-id><pub-id pub-id-type="pmcid">PMC9980699</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Martin</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Grimaldi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Grempler</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hansel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name></person-group>. <article-title>Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2191301</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2191301</pub-id>.<pub-id pub-id-type="pmid">36998195</pub-id><pub-id pub-id-type="pmcid">PMC10072077</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mieczkowski</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Way</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gries</surname><given-names>J-M</given-names></string-name></person-group>. <article-title>Blueprint for antibody biologics developability</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2185924</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2185924</pub-id>.<pub-id pub-id-type="pmid">36880643</pub-id><pub-id pub-id-type="pmcid">PMC10012935</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Svilenov</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Arosio</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Menzen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tessier</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sormanni</surname><given-names>P</given-names></string-name></person-group>. <article-title>Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2164459</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2022.2164459</pub-id>.<pub-id pub-id-type="pmid">36629855</pub-id><pub-id pub-id-type="pmcid">PMC9839375</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics</article-title>. <source>Antib Ther</source>. <year>2022</year>;<volume>6</volume>(<issue>1</issue>):<fpage>13</fpage>&#8211;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1093/abt/tbac029</pub-id>.<pub-id pub-id-type="pmid">36683767</pub-id><pub-id pub-id-type="pmcid">PMC9847343</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ahmed</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Scheer</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Nixon</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name></person-group>. <article-title>Intrinsic physicochemical profile of marketed antibody-based biotherapeutics</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2021</year>;<volume>118</volume>(<issue>37</issue>):<fpage>e2020577118</fpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2020577118</pub-id>.<pub-id pub-id-type="pmid">34504010</pub-id><pub-id pub-id-type="pmcid">PMC8449350</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bailly</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mieczkowski</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Juan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Metwally</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tomazela</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Uchida</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kofman</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Raoufi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Motlagh</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Predicting antibody developability profiles through early stage discovery screening</article-title>. <source>MAbs</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1743053</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2020.1743053</pub-id>.<pub-id pub-id-type="pmid">32249670</pub-id><pub-id pub-id-type="pmcid">PMC7153844</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Evers</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Borisovska</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Warszawski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fomekong Nanfack</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kuhn</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rippmann</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Crespo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sood</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Malhotra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bolick</surname><given-names>WG</given-names></string-name>, et al</person-group>. <part-title>Chapter 22: SUMO: In Silico Sequence Assessment Using Multiple Optimization Parameters</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Zielonka</surname><given-names>S</given-names></string-name><string-name name-style="western"><surname>Krah</surname><given-names>S</given-names></string-name></person-group>, editors. <source>Genotype phenotype coupling: methods and protocols</source>. <publisher-name>Springer US</publisher-name>; <year>2023</year>. p. <fpage>383</fpage>&#8211;<lpage>398</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-0716-3279-6_22</pub-id>.<pub-id pub-id-type="pmid">37405660</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jain</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Boland</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>V&#225;squez</surname><given-names>M</given-names></string-name></person-group>. <article-title>Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and <italic toggle="yes">in silico</italic> approaches</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2200540</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2200540</pub-id>.<pub-id pub-id-type="pmid">37072706</pub-id><pub-id pub-id-type="pmcid">PMC10114995</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jain</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Durand</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Houston</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Nett</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Sharkey</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bobrowicz</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Caffry</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Biophysical properties of the clinical-stage antibody landscape</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2017</year>;<volume>114</volume>(<issue>5</issue>):<fpage>944</fpage>&#8211;<lpage>949</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1616408114</pub-id>.<pub-id pub-id-type="pmid">28096333</pub-id><pub-id pub-id-type="pmcid">PMC5293111</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Licari</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Crames</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mozdzierz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Marlow</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Karow-Zwick</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bauer</surname><given-names>J</given-names></string-name></person-group>. <article-title>Embedding dynamics in intrinsic physicochemical profiles of market-stage antibody-based biotherapeutics</article-title>. <source>Mol Pharm</source>. <year>2023</year>;<volume>20</volume>(<issue>2</issue>):<fpage>1096</fpage>&#8211;<lpage>1111</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00838</pub-id>.<pub-id pub-id-type="pmid">36573887</pub-id><pub-id pub-id-type="pmcid">PMC9906779</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Makowski</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H-T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mock</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Underhill</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pelegri-O&#8217;Day</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Maglalang</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Winters</surname><given-names>D</given-names></string-name>, et al</person-group>. <article-title>Reduction of monoclonal antibody viscosity using interpretable machine learning</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2303781</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2303781</pub-id>.<pub-id pub-id-type="pmid">38475982</pub-id><pub-id pub-id-type="pmcid">PMC10939158</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mock</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jacobitz</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Langmead</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Sudom</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Humphreys</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Alday</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alekseychyk</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Angell</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bi</surname><given-names>V</given-names></string-name>, et al</person-group>. <article-title>Development of <italic toggle="yes">in silico</italic> models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2256745</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2256745</pub-id>.<pub-id pub-id-type="pmid">37698932</pub-id><pub-id pub-id-type="pmcid">PMC10498806</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Negron</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McPherson</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Stine</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>McCluskey</surname><given-names>AJ</given-names></string-name></person-group>. <article-title>Separating clinical antibodies from repertoire antibodies, a path to <italic toggle="yes">in silico</italic> developability assessment</article-title>. <source>MAbs</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>2080628</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2022.2080628</pub-id>.<pub-id pub-id-type="pmid">35771588</pub-id><pub-id pub-id-type="pmcid">PMC9255221</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Izadi</surname><given-names>S</given-names></string-name></person-group>. <article-title>Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2362788</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2362788</pub-id>.<pub-id pub-id-type="pmid">38853585</pub-id><pub-id pub-id-type="pmcid">PMC11168226</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raybould</surname><given-names>MIJ</given-names></string-name>, <string-name name-style="western"><surname>Marks</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Krawczyk</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Taddese</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nowak</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Bujotzek</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deane</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Five computational developability guidelines for therapeutic antibody profiling</article-title>. <source>Proc Natl Acad Sci, India, Sect B Biol Sci</source>. <year>2019</year>;<volume>116</volume>(<issue>10</issue>):<fpage>4025</fpage>&#8211;<lpage>4030</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1810576116</pub-id>.<pub-id pub-id-type="pmcid">PMC6410772</pub-id><pub-id pub-id-type="pmid">30765520</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Waight</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Prihoda</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shrestha</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Metcalf</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bailly</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ancona</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Widatalla</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rollins</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Bitton</surname><given-names>DA</given-names></string-name>, et al</person-group>. <article-title>A machine learning strategy for the identification of key <italic toggle="yes">in silico</italic> descriptors and prediction models for IgG monoclonal antibody developability properties</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2248671</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2248671</pub-id>.<pub-id pub-id-type="pmid">37610144</pub-id><pub-id pub-id-type="pmcid">PMC10448975</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chai</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Shih</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weldon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Phan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>BE</given-names></string-name></person-group>. <article-title>Development of a high-throughput solubility screening assay for use in antibody discovery</article-title>. <source>MAbs</source>. <year>2019</year>;<volume>11</volume>(<issue>4</issue>):<fpage>747</fpage>&#8211;<lpage>756</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2019.1589851</pub-id>.<pub-id pub-id-type="pmid">30913963</pub-id><pub-id pub-id-type="pmcid">PMC6601704</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Caffry</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Reid</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Estep</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy</article-title>. <source>MAbs</source>. <year>2014</year>;<volume>6</volume>(<issue>2</issue>):<fpage>483</fpage>&#8211;<lpage>492</lpage>. doi: <pub-id pub-id-type="doi">10.4161/mabs.27431</pub-id>.<pub-id pub-id-type="pmid">24492294</pub-id><pub-id pub-id-type="pmcid">PMC3984336</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Starr</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Makowski</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kingsbury</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Gokarn</surname><given-names>YR</given-names></string-name>, <string-name name-style="western"><surname>Tessier</surname><given-names>PM</given-names></string-name></person-group>. <article-title>Ultradilute measurements of self-association for the identification of antibodies with favorable high-concentration solution properties</article-title>. <source>Mol Pharm</source>. <year>2021</year>;<volume>18</volume>(<issue>7</issue>):<fpage>2744</fpage>&#8211;<lpage>2753</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00280</pub-id>.<pub-id pub-id-type="pmid">34105965</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Weldon</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Sule</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Chai</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Dickinson</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Tessier</surname><given-names>PM</given-names></string-name></person-group>. <article-title>Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy</article-title>. <source>Protein Eng Des Sel</source>. <year>2015</year>;<volume>28</volume>(<issue>10</issue>):<fpage>403</fpage>&#8211;<lpage>414</lpage>. doi: <pub-id pub-id-type="doi">10.1093/protein/gzv045</pub-id>.<pub-id pub-id-type="pmid">26363633</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harding</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>P</given-names></string-name></person-group>. <article-title>The concentration-dependence of macromolecular parameters</article-title>. <source>Biochemical J</source>. <year>1985</year>;<volume>231</volume>(<issue>3</issue>):<fpage>543</fpage>&#8211;<lpage>547</lpage>. doi: <pub-id pub-id-type="doi">10.1042/bj2310543</pub-id>.<pub-id pub-id-type="pmcid">PMC1152785</pub-id><pub-id pub-id-type="pmid">4074322</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kingsbury</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Saini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Auclair</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lantz</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Halloran</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Calero-Rubio</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schwenger</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Airiau</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>A single molecular descriptor to predict solution behavior of therapeutic antibodies</article-title>. <source>Sci Adv</source>. <year>2020</year>;<volume>6</volume>(<issue>32</issue>):<fpage>eabb0372</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.abb0372</pub-id>.<pub-id pub-id-type="pmid">32923611</pub-id><pub-id pub-id-type="pmcid">PMC7457339</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Desai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kundu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hageman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Boisvert</surname><given-names>D</given-names></string-name></person-group>. <article-title>Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2285277</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2285277</pub-id>.<pub-id pub-id-type="pmid">38013454</pub-id><pub-id pub-id-type="pmcid">PMC10793682</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brudar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Breydo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dill</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Ehterami</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Phadnis</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Senapati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shameem</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tayyab</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Antibody association in solution: cluster distributions and mechanisms</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2339582</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2339582</pub-id>.<pub-id pub-id-type="pmid">38666507</pub-id><pub-id pub-id-type="pmcid">PMC11057677</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gentiluomo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Roessner</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Streicher</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mahapatra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Frie&#223;</surname><given-names>W</given-names></string-name></person-group>. <article-title>Characterization of native reversible self-association of a monoclonal antibody mediated by Fab-Fab interaction</article-title>. <source>J Pharm Sci</source>. <year>2020</year>;<volume>109</volume>(<issue>1</issue>):<fpage>443</fpage>&#8211;<lpage>451</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xphs.2019.09.021</pub-id>.<pub-id pub-id-type="pmid">31563513</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kanai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Patapoff</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Shire</surname><given-names>SJ</given-names></string-name></person-group>. <article-title>Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity</article-title>. <source>J Pharm Sci</source>. <year>2008</year>;<volume>97</volume>(<issue>10</issue>):<fpage>4219</fpage>&#8211;<lpage>4227</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jps.21322</pub-id>.<pub-id pub-id-type="pmid">18240303</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lilyestrom</surname><given-names>WG</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shire</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Scherer</surname><given-names>TM</given-names></string-name></person-group>. <article-title>Monoclonal antibody self-association, cluster formation, and rheology at high concentrations</article-title>. <source>J Phys Chem B</source>. <year>2013</year>;<volume>117</volume>(<issue>21</issue>):<fpage>6373</fpage>&#8211;<lpage>6384</lpage>. doi: <pub-id pub-id-type="doi">10.1021/jp4008152</pub-id>.<pub-id pub-id-type="pmid">23560896</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mieczkowski</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fischmann</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hsieh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Uchida</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Raghunathan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Strickland</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fayadat-Dilman</surname><given-names>L</given-names></string-name></person-group>. <article-title>Characterization and modeling of reversible antibody self-association provide insights into behavior, prediction, and correction</article-title>. <source>Antibodies</source>. <year>2021</year>;<volume>10</volume>(<issue>1</issue>):<fpage>8</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antib10010008</pub-id>.<pub-id pub-id-type="pmid">33671864</pub-id><pub-id pub-id-type="pmcid">PMC7931086</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yearley</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Godfrin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Perevozchikova</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Falus</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Porcar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nagao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Curtis</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gawande</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Taing</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Observation of small cluster formation in concentrated monoclonal antibody solutions and its implications to solution viscosity</article-title>. <source>Biophys J</source>. <year>2014</year>;<volume>106</volume>(<issue>8</issue>):<fpage>1763</fpage>&#8211;<lpage>1770</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bpj.2014.02.036</pub-id>.<pub-id pub-id-type="pmid">24739175</pub-id><pub-id pub-id-type="pmcid">PMC4008822</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agrawal</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Helk</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mody</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sathish</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Samra</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Buck</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Trout</surname><given-names>BL</given-names></string-name></person-group>. <article-title>Computational tool for the early screening of monoclonal antibodies for their viscosities</article-title>. <source>MAbs</source>. <year>2016</year>;<volume>8</volume>(<issue>1</issue>):<fpage>43</fpage>&#8211;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2015.1099773</pub-id>.<pub-id pub-id-type="pmid">26399600</pub-id><pub-id pub-id-type="pmcid">PMC4966561</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bashour</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Smorodina</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pariset</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Akbar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chernigovskaya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>L&#234; Qu&#253;</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Snapkow</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Rawat</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Krawczyk</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability</article-title>. <source>Commun Biol</source>. <year>2024</year>;<volume>7</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s42003-024-06561-3</pub-id>.<pub-id pub-id-type="pmid">39085379</pub-id><pub-id pub-id-type="pmcid">PMC11291509</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Izadi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zarzar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG1 antibody</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2304282</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2304282</pub-id>.<pub-id pub-id-type="pmid">38269489</pub-id><pub-id pub-id-type="pmcid">PMC10813588</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gupta</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Makowski</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Scheer</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Tessier</surname><given-names>PM</given-names></string-name></person-group>. <article-title>Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties</article-title>. <source>Mol Pharm</source>. <year>2022</year>;<volume>19</volume>(<issue>3</issue>):<fpage>775</fpage>&#8211;<lpage>787</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00373</pub-id>.<pub-id pub-id-type="pmid">35108018</pub-id><pub-id pub-id-type="pmcid">PMC9350878</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rai</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Apgar</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>EM</given-names></string-name></person-group>. <article-title>Low-data interpretable deep learning prediction of antibody viscosity using a biophysically meaningful representation</article-title>. <source>Sci Rep</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>2917</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-28841-4</pub-id>.<pub-id pub-id-type="pmid">36806303</pub-id><pub-id pub-id-type="pmcid">PMC9941094</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharma</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Patapoff</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Kabakoff</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hilario</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Borisov</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Kelley</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Chorny</surname><given-names>I</given-names></string-name>, et al</person-group>. <article-title><italic toggle="yes">In silico</italic> selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2014</year>;<volume>111</volume>(<issue>52</issue>):<fpage>18601</fpage>&#8211;<lpage>18606</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1421779112</pub-id>.<pub-id pub-id-type="pmid">25512516</pub-id><pub-id pub-id-type="pmcid">PMC4284567</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tomar</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Broulidakis</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Luksha</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name></person-group>. <article-title><italic toggle="yes">In-silico</italic> prediction of concentration-dependent viscosity curves for monoclonal antibody solutions</article-title>. <source>MAbs</source>. <year>2017</year>;<volume>9</volume>(<issue>3</issue>):<fpage>476</fpage>&#8211;<lpage>489</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2017.1285479</pub-id>.<pub-id pub-id-type="pmid">28125318</pub-id><pub-id pub-id-type="pmcid">PMC5384706</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cain</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Anguiano</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Impact of IgG subclass on monoclonal antibody developability</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2191302</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2191302</pub-id>.<pub-id pub-id-type="pmid">36945111</pub-id><pub-id pub-id-type="pmcid">PMC10038059</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heisler</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kovner</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Izadi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zarzar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations</article-title>. <source>MAbs</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>2379560</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2024.2379560</pub-id>.<pub-id pub-id-type="pmid">39028186</pub-id><pub-id pub-id-type="pmcid">PMC11262234</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sawant</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Streu</surname><given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tessier</surname><given-names>PM</given-names></string-name></person-group>. <article-title>Toward drug-like multispecific antibodies by design</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>20</issue>):<fpage>7496</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21207496</pub-id>.<pub-id pub-id-type="pmid">33053650</pub-id><pub-id pub-id-type="pmcid">PMC7589779</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pang</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Sormanni</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Michaels</surname><given-names>TCT</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Chia</surname><given-names>S</given-names></string-name></person-group>. <article-title>Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics</article-title>. <source>Biotechnol Adv</source>. <year>2023</year>;<volume>67</volume>:<fpage>108192</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biotechadv.2023.108192</pub-id>.<pub-id pub-id-type="pmid">37290583</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sahin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Grillo</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Perkins</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Comparative effects of pH and ionic strength on protein&#8211;protein interactions, unfolding, and aggregation for IgG1 antibodies</article-title>. <source>J Pharm Sci</source>. <year>2010</year>;<volume>99</volume>(<issue>12</issue>):<fpage>4830</fpage>&#8211;<lpage>4848</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jps.22198</pub-id>.<pub-id pub-id-type="pmid">20821389</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kumru</surname><given-names>OS</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>John Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Russell Middaugh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Volkin</surname><given-names>DB</given-names></string-name></person-group>. <article-title>Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment</article-title>. <source>J Pharm Sci</source>. <year>2013</year>;<volume>102</volume>(<issue>8</issue>):<fpage>2520</fpage>&#8211;<lpage>2537</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jps.23645</pub-id>.<pub-id pub-id-type="pmid">23824562</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mahn</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lienqueo</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Asenjo</surname><given-names>JA</given-names></string-name></person-group>. <article-title>Optimal operation conditions for protein separation in hydrophobic interaction chromatography</article-title>. <source>J Chromatogr B</source>. <year>2007</year>;<volume>849</volume>(<issue>1&#8211;2</issue>):<fpage>236</fpage>&#8211;<lpage>242</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jchromb.2006.09.013</pub-id>.<pub-id pub-id-type="pmid">17027350</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Queiroz</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Tomaz</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Cabral</surname><given-names>JMS</given-names></string-name></person-group>. <article-title>Hydrophobic interaction chromatography of proteins</article-title>. <source>J biotechnol</source>. <year>2001</year>;<volume>87</volume>(<issue>2</issue>):<fpage>143</fpage>&#8211;<lpage>159</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0168-1656(01)00237-1</pub-id>.<pub-id pub-id-type="pmid">11278038</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Niedziela-Majka</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kan</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Weissburg</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mehra</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Sellers</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sakowicz</surname><given-names>R</given-names></string-name></person-group>. <article-title>High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody</article-title>. <source>SLAS Discov</source>. <year>2015</year>;<volume>20</volume>(<issue>4</issue>):<fpage>552</fpage>&#8211;<lpage>559</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1087057114557781</pub-id>.<pub-id pub-id-type="pmid">25385011</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fukada</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tsumoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Arakawa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ejima</surname><given-names>D</given-names></string-name></person-group>. <article-title>Long-term stability and reversible thermal unfolding of antibody structure at low pH: case study</article-title>. <source>J Pharm Sci</source>. <year>2018</year>;<volume>107</volume>(<issue>11</issue>):<fpage>2965</fpage>&#8211;<lpage>2967</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xphs.2018.07.001</pub-id>.<pub-id pub-id-type="pmid">30017886</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hebditch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kean</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Warwicker</surname><given-names>J</given-names></string-name></person-group>. <article-title>Modelling of pH-dependence to develop a strategy for stabilising mAbs at acidic steps in production</article-title>. <source>Comput Struct Biotechnol J</source>. <year>2020</year>;<volume>18</volume>:<fpage>897</fpage>&#8211;<lpage>905</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.csbj.2020.03.002</pub-id>.<pub-id pub-id-type="pmid">32322371</pub-id><pub-id pub-id-type="pmcid">PMC7171260</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ito</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tsumoto</surname><given-names>K</given-names></string-name></person-group>. <article-title>Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress</article-title>. <source>Protein Sci</source>. <year>2013</year>;<volume>22</volume>(<issue>11</issue>):<fpage>1542</fpage>&#8211;<lpage>1551</lpage>. doi: <pub-id pub-id-type="doi">10.1002/pro.2340</pub-id>.<pub-id pub-id-type="pmid">23963869</pub-id><pub-id pub-id-type="pmcid">PMC3831669</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Welfle</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Misselwitz</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hausdorf</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>H&#246;hne</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Welfle</surname><given-names>H</given-names></string-name></person-group>. <article-title>Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments</article-title>. <source>Biochim Et Biophys Acta (BBA) - Protein Struct Mol Enzymol</source>. <year>1999</year>;<volume>1431</volume>(<issue>1</issue>):<fpage>120</fpage>&#8211;<lpage>131</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0167-4838(99)00046-1</pub-id>.<pub-id pub-id-type="pmid">10209285</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="book"><source>Molecular operating environment (MOE)</source>. <publisher-loc>Montreal, QC, Canada</publisher-loc>: <publisher-name>Chemical Computing Group ULC</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Datta-Mannan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Witcher</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Leung</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wroblewski</surname><given-names>VJ</given-names></string-name></person-group>. <article-title>The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies</article-title>. <source>MAbs</source>. <year>2015</year>;<volume>7</volume>(<issue>6</issue>):<fpage>1084</fpage>&#8211;<lpage>1093</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2015.1075109</pub-id>.<pub-id pub-id-type="pmid">26337808</pub-id><pub-id pub-id-type="pmcid">PMC4966429</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tabrizi</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>C-ML</given-names></string-name>, <string-name name-style="western"><surname>Roskos</surname><given-names>LK</given-names></string-name></person-group>. <article-title>Elimination mechanisms of therapeutic monoclonal antibodies</article-title>. <source>Drug Discov Today Today</source>. <year>2006</year>;<volume>11</volume>(<issue>1&#8211;2</issue>):<fpage>81</fpage>&#8211;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1359-6446(05)03638-X</pub-id>.<pub-id pub-id-type="pmid">16478695</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bumbaca</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Boswell</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Fielder</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Khawli</surname><given-names>LA</given-names></string-name></person-group>. <article-title>Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics</article-title>. <source>AAPS J</source>. <year>2012</year>;<volume>14</volume>(<issue>3</issue>):<fpage>554</fpage>&#8211;<lpage>558</lpage>. doi: <pub-id pub-id-type="doi">10.1208/s12248-012-9369-y</pub-id>.<pub-id pub-id-type="pmid">22610647</pub-id><pub-id pub-id-type="pmcid">PMC3385840</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kraft</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Richter</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Emrich</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Knaupp</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schuster</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wolfert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kettenberger</surname><given-names>H</given-names></string-name></person-group>. <article-title>Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis</article-title>. <source>MAbs</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1683432</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2019.1683432</pub-id>.<pub-id pub-id-type="pmid">31769731</pub-id><pub-id pub-id-type="pmcid">PMC6927760</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kettenberger</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Richter</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>DK</given-names></string-name></person-group>. <article-title>Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies</article-title>. <source>MAbs</source>. <year>2021</year>;<volume>13</volume>(<issue>1</issue>):<fpage>1993769</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2021.1993769</pub-id>.<pub-id pub-id-type="pmid">34711143</pub-id><pub-id pub-id-type="pmcid">PMC8565835</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>H-T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sawant</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Rajagopal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Desai</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Makowski</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Licari</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions</article-title>. <source>Cell Rep</source>. <year>2024</year>;<volume>43</volume>(<issue>10</issue>):<fpage>114801</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2024.114801</pub-id>.<pub-id pub-id-type="pmid">39392756</pub-id><pub-id pub-id-type="pmcid">PMC11564698</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buchanan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Croasdale-Wood</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Evers</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fennell</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Furtmann</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Krawczyk</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Langmead</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Shahsavarian</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>How to think about designing smart antibodies in the age of genAI: integrating biology, technology, and experience</article-title>. <source>MAbs</source>. <year>2025</year>;<volume>17</volume>(<issue>1</issue>):<fpage>2490790</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2025.2490790</pub-id>.<pub-id pub-id-type="pmid">40211100</pub-id><pub-id pub-id-type="pmcid">PMC11999353</pub-id></mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lv</surname><given-names>J-Y</given-names></string-name>, <string-name name-style="western"><surname>Ingle</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>W-J</given-names></string-name></person-group>. <article-title>Histidine as a versatile excipient in the protein-based biopharmaceutical formulations</article-title>. <source>Int J Multiling Pharm</source>. <year>2024</year>;<volume>662</volume>:<fpage>124472</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124472</pub-id>.<pub-id pub-id-type="pmid">39013532</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saurabh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kalonia</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hollowell</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Waigh</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Webster</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Seddon</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Bresme</surname><given-names>F</given-names></string-name></person-group>. <article-title>Understanding the stabilizing effect of histidine on mAb aggregation: a molecular dynamics study</article-title>. <source>Mol Pharm</source>. <year>2022</year>;<volume>19</volume>(<issue>9</issue>):<fpage>3288</fpage>&#8211;<lpage>3303</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00453</pub-id>.<pub-id pub-id-type="pmid">35946408</pub-id><pub-id pub-id-type="pmcid">PMC9449975</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fern&#225;ndez-Quintero</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Guarnera</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Musil</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pekar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sellmann</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Freire</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sousa</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Freitas</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Bandeiras</surname><given-names>TM</given-names></string-name>, et al</person-group>. <article-title>On the humanization of VHHs: prospective case studies, experimental and computational characterization of structural determinants for functionality</article-title>. <source>Protein Sci</source>. <year>2024</year>;<volume>33</volume>(<issue>11</issue>):<fpage>e5176</fpage>. doi: <pub-id pub-id-type="doi">10.1002/pro.5176</pub-id>.<pub-id pub-id-type="pmid">39422475</pub-id><pub-id pub-id-type="pmcid">PMC11487682</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gordon</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Raybould</surname><given-names>MIJ</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Deane</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Prospects for the computational humanization of antibodies and nanobodies</article-title>. <source>Front Immunol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1399438</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2024.1399438</pub-id>.<pub-id pub-id-type="pmid">38812514</pub-id><pub-id pub-id-type="pmcid">PMC11133524</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Sulea</surname><given-names>T</given-names></string-name></person-group><source>Humanization of camelid single-domain antibodies. In</source>: <person-group person-group-type="editor"><string-name name-style="western"><surname>Hussack</surname>, <given-names>G.</given-names></string-name> &amp; <string-name name-style="western"><surname>Henry</surname>, <given-names>K. A</given-names></string-name></person-group>, editors. <publisher-loc>Single-domain antibodies: methods and protocols. New York (NY)</publisher-loc>: <publisher-name>Springer US</publisher-name>; <year>2022</year>. p. <fpage>299</fpage>&#8211;<lpage>312</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-0716-2075-5_14</pub-id>.<pub-id pub-id-type="pmid">35157279</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>B&#233;langer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sulea</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>van Faassen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Callaghan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Aubry</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sasseville</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hussack</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tanha</surname><given-names>J</given-names></string-name></person-group>. <article-title>Optimization of synthetic human VH affinity and solubility through in vitro affinity maturation and minimal camelization</article-title>. <source>Protein Sci</source>. <year>2025</year>;<volume>34</volume>(<issue>5</issue>):<fpage>e70114</fpage>. doi: <pub-id pub-id-type="doi">10.1002/pro.70114</pub-id>.<pub-id pub-id-type="pmid">40260965</pub-id><pub-id pub-id-type="pmcid">PMC12012759</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ramon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Greenig</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sormanni</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Adamio</surname><given-names>L</given-names></string-name></person-group>. <article-title>Development of potent humanized TNF&#945; inhibitory nanobodies for therapeutic applications in TNF&#945;-mediated diseases</article-title>. <source>MAbs</source>. <year>2025</year>;<volume>17</volume>(<issue>1</issue>):<fpage>2498164</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2025.2498164</pub-id>.<pub-id pub-id-type="pmid">40367237</pub-id><pub-id pub-id-type="pmcid">PMC12080732</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Evers</surname><given-names>A</given-names></string-name></person-group>. <article-title>Sumo: <italic toggle="yes">in silico</italic> sequence assessment using multiple optimization parameters</article-title>. <source>Methods Mol Biol</source>. <year>2023</year>;<volume>2681</volume>:<fpage>383</fpage>&#8211;<lpage>398</lpage>.<pub-id pub-id-type="pmid">37405660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-3279-6_22</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arras</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Pekar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schr&#246;ter</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Krah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Klewinghaus</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Siegmund</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Evers</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zielonka</surname><given-names>S</given-names></string-name></person-group>. <article-title>A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2261149</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2261149</pub-id>.<pub-id pub-id-type="pmid">37766540</pub-id><pub-id pub-id-type="pmcid">PMC10540653</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Arras</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Pekar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Friedrich</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schr&#246;ter</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schanz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tonillo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Siegmund</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Doerner</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>AI/ml combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study</article-title>. <source>Front Mol biosci</source>. <year>2023</year>;<volume>10</volume>:<fpage>1249247</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmolb.2023.1249247</pub-id>.<pub-id pub-id-type="pmid">37842638</pub-id><pub-id pub-id-type="pmcid">PMC10575757</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ollier</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fuchs</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gauye</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Piorkowska</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Menant</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ratnam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Montanari</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Guilhot</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Phillipe</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Audrain</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework</article-title>. <source>MAbs</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>2232087</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19420862.2023.2232087</pub-id>.<pub-id pub-id-type="pmid">37408314</pub-id><pub-id pub-id-type="pmcid">PMC10324452</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cock</surname><given-names>PJA</given-names></string-name>, <string-name name-style="western"><surname>Antao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Chapman</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Dalke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Friedberg</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hamelryck</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kauff</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wilczynski</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Biopython: freely available Python tools for computational molecular biology and bioinformatics</article-title>. <source>Bioinformatics</source>. <year>2009</year>;<volume>25</volume>(<issue>11</issue>):<fpage>1422</fpage>&#8211;<lpage>1423</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btp163</pub-id>.<pub-id pub-id-type="pmid">19304878</pub-id><pub-id pub-id-type="pmcid">PMC2682512</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>